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‘It would be nice if the Food and Drug Administration  
stopped issuing warnings about toxic substances  
and just gave me the names of one or two things  
still safe to eat.’ 
 
Robert Fuoss (1912-1980) 
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Summary  
Food contains toxicants which may exert adverse effects on the immune system. The result 
can be immune-related diseases such as allergy, asthma and autoimmune conditions, or 
increased susceptibility to infectious diseases and cancer. The overall aim of the present work 
was to investigate the immunotoxic potential of dietary toxicants, with focus on prenatal 
exposure to toxicants from the maternal diet. Prenatal exposure to immunotoxicants is of 
particular concern since the foetus may be especially vulnerable due to an extensively 
developing immune system. 
 To examine whether release of cytokines in an in vitro system can be used as a marker 
of immunotoxic properties of dietary toxicants, human peripheral blood mononuclear cells 
were exposed in vitro to 12 dietary toxicants. Both immunotoxic and non-immunotoxic 
substances, classified according to published in vivo studies, were included. All 12 dietary 
toxicants affected the release of one or more of the nine cytokines included, and the exposure 
to each of the toxicants resulted in different cytokine release patterns. Although the effects on 
the release of each cytokine were examined separately and in combinations of cytokines, the 
in vitro cytokine release could not be used to differentiate between the immunotoxic and the 
non-immunotoxic substances. 
Of the 12 dietary toxicants, the environmental pollutants polychlorinated biphenyls 
(PCBs) and dioxins, as well as acrylamide formed during food preparation, were chosen for 
further examination in a birth cohort. The birth cohort BraMat (n=205), a sub-cohort of the 
Norwegian Mother and Child Cohort Study (MoBa), was established to investigate whether 
prenatal exposure to these toxicants from the maternal diet increases the risk of immune-
related diseases in the child. The children were followed using annual questionnaires covering 
health outcomes during their three first years of life. Immune-related blood parameters were 
examined at three years of age. The maternal intake of the toxicants during pregnancy was 
calculated using a validated food frequency questionnaire from MoBa, and the levels were 
assumed to be representative for the general population. Prenatal dietary exposure to PCBs 
and dioxins was found to be associated with an increased risk of wheeze (periods of more 
than 10 days with dry cough, chest tightness or wheeze, or shortness of breath), the childhood 
disease exanthema subitum and more frequent upper respiratory tract infections during the 
three first years of life. Further, at three years of age, exposure to PCBs and dioxins was 
found to be associated with a reduced antibody response to measles vaccine. No associations 
were found between prenatal exposure to PCBs and dioxins and immunophenotype data 
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including levels of regulatory T cells, allergic sensitization or antibody responses to other 
vaccines than measles. Prenatal acrylamide exposure was not found to be associated with any 
of the children’s health outcomes or blood parameters.  
 In conclusion, the in vitro study, within the limitations of the study design, does not 
support the replacement of in vivo studies with in vitro cytokine release studies for 
identification of immunotoxic substances. In the BraMat cohort, prenatal exposure to 
acrylamide from the maternal diet was not found to be associated with immune-related health 
outcomes or blood parameters, but the statistical power may be too low to conclude on 
negative findings. However, prenatal exposure to PCBs and dioxins from the maternal diet 
may increase the risk of wheeze and the susceptibility to infectious diseases during early 
childhood. Overall, continued efforts to reduce the exposure to PCBs and dioxins from food 
for women of fertile age may be beneficial for their children’s health.  
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1 Introduction 
1.1 The immune system 
The immune system is protecting the body against infectious agents and the development of 
tumors (Bogen and Munthe, 2007; Murphy et al., 2008). The immune system consists of a 
number of lymphoid organs, a variety of cells and soluble mediators. The lymphoid organs 
can be divided into central and peripheral lymphoid organs. The central organs consist of the 
bone marrow and the thymus, and the peripheral organs of the lymph nodes, the spleen and 
the mucosal lymphoid tissues. 
  The immune system can be divided into the adaptive and the innate immune system. 
The adaptive immune system develops an immune response with a high degree of specificity 
against an infectious agent, which may result in specific, long-lasting protection 
(immunological memory). In contrast, the innate immune system develops a faster, non-
specific response to a wide range of agents which does not result in immunological memory.  
1.1.1 Immune cells and mediators 
The cells of the immune system are called white blood cells or leukocytes, which can be 
divided into several types and subtypes with different effector functions (Bogen and Munthe, 
2007; Murphy et al., 2008). The two main categories of leukocytes are the myeloid and the 
lymphoid lineages. The myeloid lineage comprises the majority of the cells of the innate 
immune system and consists of monocytes, macrophages (mature form of monocytes), 
granulocytes (neutrophils, basophils and eosinophils), mast cells and dendritic cells. The 
lymphoid lineage consists of the lymphocytes of the adaptive immune system and the natural 
killer (NK) cells of the innate immune system. The two main types of lymphocytes are B 
lymphocytes (B cells) and T lymphocytes (T cells). The immune cells express clusters of 
differentiation (CD) markers on their surface (membrane molecules), and the various 
expressions of CD markers on the immune cells can be used to distinguish between the 
different subtypes and maturation states.  
The leukocytes communicate via direct cell-cell contact and via secretion and binding 
of cytokines and chemokines (Bogen and Munthe, 2007; Murphy et al., 2008). Cytokines are 
small proteins produced by a cell that affect the function of cells with the appropriate 
receptor, while chemokines are small proteins that attract cells bearing their receptor. The 
different types of leukocytes release different sets of cytokines which are important for their 
Introduction 
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respective functions. In Table 2 (section 3.3), examples of cytokines, their producer cells and 
their effects are shown. 
1.1.2 Immune response 
The innate and the adaptive immune system is cooperating in protecting the human body 
against infectious agents (Bogen and Munthe, 2007; Murphy et al., 2008). The innate immune 
system acts immediately upon exposure to invading infectious agents. The main functions of 
the cells of the innate immune system are to destroy pathogens by phagocytosis, induce 
inflammation, activate and recruit other leukocytes, and to present antigens to T cells and 
activate them. Antigens are usually molecules from the pathogens which the immune system 
may respond to. The antigen presenting cells, such as dendritic cells, form a crucial link 
between the innate and the adaptive immune response.  
In general, the adaptive immune response reinforces the innate immune response. The 
adaptive immune system is capable of eliminating infections more efficiently than the innate 
immune system, but an adaptive immune response may take days to develop (Bogen and 
Munthe, 2007; Murphy et al., 2008). The adaptive immune response is divided into cell-
mediated and humoral (antibody-mediated) responses. The T cells are crucial for developing 
the cell-mediated responses. T-helper (h) 1 cells can fight intracellular bacterial infections in 
macrophages by e.g. activating infected macrophages to destroy the pathogens. Cytotoxic T 
cells may directly kill cells infected with viruses if they display viral antigens (Horst et al., 
2011). Th17 cells seem to be important in recruiting neutrophils to control the early stages of 
an infection (Miossec, 2009). Unlike Th1 cells, cytotoxic T cells and Th17 cells, regulatory T 
cells restrain inflammation and maintain tolerance to harmless antigens, including self 
antigens (Curotto de Lafaille and Lafaille, 2009; Sanchez and Yang, 2011). In the humoral 
immune response, antibodies are the important factors for fighting extracellular invading 
infectious agents and harmful molecules. Th2 cells, but also Th1 cells, (Mosmann et al., 
1986) stimulate B cells to produce such antibodies (Bogen and Munthe, 2007; Murphy et al., 
2008). The antibodies may bind to pathogens or their products and neutralize them by 
blocking their access to cells. Furthermore, different parts of the antibodies may bind to 
antigens and elements of the innate immune system simultaneously, which results in an 
effective elimination of the pathogens by e.g. ingestion by phagocytes (opsonization) or 
activation of the complement system. The complement system is part of the innate immune 
system and consists of a cascade system of plasma proteins that interact to opsonize 
pathogens, to kill directly by lysis and to induce a series of inflammatory responses to fight 
Introduction 
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infections. Antibodies are divided into the different classes called IgD, IgM, IgG, IgA and 
IgE, and all classes have different effector functions. IgM is the first class of antibody 
secreted during an immune response and is important in activating the complement system. 
Later, IgG and IgA are the predominant antibody classes. IgG is mainly involved in fighting 
pathogens in the blood and the extracellular fluid, whereas IgA is mainly involved in 
neutralizing pathogens in the airways and the gastro-intestinal tract (mucosal antibody). IgE 
antibodies are usually present at low levels in the blood and the extracellular fluid, but may 
bind to mast cells, basophils and activated eosinophils. Antigens when cross-binding cell-
bound IgE, can (further) activate the cells. IgE-mediated responses are characteristic for 
allergic diseases (Akdis, 2006), however, allergic reactions can also be independent of IgE 
(see section 1.2) (Bogen and Munthe, 2007; Murphy et al., 2008). 
 
1.2 Immunotoxicology 
Immunotoxicology is a relatively new discipline in toxicology (Burleson and Dean, 1995; 
Descotes, 1999). Adverse effects of chemicals on the immune system were reported in several 
studies, and in 1977 Vos et al. concluded that standard toxicity testing in animals 
underestimated chemical effects on the immune system (Vos, 1977). The first scientific 
symposia on this topic were at the Annals of the New York Academy of Science meeting in 
1979, followed by a Gordon Research Conference, and reported by Dean et al. (1979) in a 
special issue of the journal of Drug and Chemical Toxicology. This special issue may be 
regarded as one of the foundation texts of the discipline of immunotoxicology. The ‘birth’ of 
this discipline was formally announced by Davies in 1983 (Davies, 1983). In 1984, a seminar 
was held in Luxembourg, which is widely regarded as a hallmark in the history of 
immunotoxicology (Descotes, 1999). 
Several definitions of immunotoxicology exist. This discipline of toxicology can 
informally be defined as the science that deals with changes of the immune system induced by 
substances (Flaherty, 2005). A change refers to any adverse effect on the structure or function 
of the immune system, or on other systems as a result of immune system dysfunction. The 
adverse effects include immunosuppression, hypersensitivity and autoimmunity (Figure 1). 
Immunosuppression may result in increased susceptibility to infections and cancer. 
Accordingly, an increased risk of cancer and severe infections in transplant recipients 
receiving immunosuppressive therapy to avoid transplant rejections have been reported (Buell 
et al., 2005; Engels et al., 2011; Horl et al., 2002; Vial and Descotes, 2003). Hypersensitivity 
Introduction 
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is defined as an inappropriate or excessive response of the adaptive immune system to various 
foreign substances (Vohr, 2005). Hypersensitivity reactions mediated by IgE-antibodies can 
result in allergic diseases such as rhinoconjunctivitis, asthma, food allergy, urticaria and 
systemic anaphylaxis (Murphy et al., 2008), whereas T-cell mediated hypersensitivity 
reactions may result in diseases such as allergic contact dermatitis. Autoimmunity is an 
immune response to antigens expressed by cells and tissues of the body (Rose, 2005). A 
critical function of the immune system is to discriminate normal self from altered self and 
non-self, but if the immune system fails, tissue-specific or systemic autoimmune diseases 
such as type 1 diabetes mellitus, multiple sclerosis, rheumatoid arthritis and systemic lupus 
erythematosus may develop. 
Sometimes also immunostimulation is included as an immunotoxic endpoint (De Jong 
and van Loveren, 2007; Descotes, 1999; Descotes, 2005), but adverse immunostimulatory 
effects are assumed to mainly result in hypersensitivity and autoimmunity. Other 
immunostimulating effects such as flu-like reactions or the more severe cytokine storm, 
exacerbation of underlying disease and inhibition of hepatic drug metabolism, have been 
reported for some drugs and vaccines (Descotes, 1999; Descotes, 2005). 
Immunotoxicity may be divided into direct and indirect immunotoxicity (Figure 1). A 
substance is considered to exert direct immunotoxicity when effects on organs or cells of the 
immune system or immune function are observed at doses not causing overt general toxicity 
(De Jong and van Loveren, 2007; Karras and Holsapple, 1996). Indirect immunotoxicity is 
when the immune system is influenced by other organs affected by the substance. The 
differentiation between direct and indirect immunotoxicity is to a certain extent artificial since 
chemicals may exert both types of immunotoxicity (De Jong and van Loveren, 2007). From 
an epidemiological point of view, it may be more important to investigate whether a chemical 
is immunotoxic or not, rather than whether it exerts direct or indirect immunotoxicity. With 
regard to mechanistic studies, however, direct versus indirect immunotoxicity is an issue of 
importance. In vitro studies may have an advantage compared to in vivo studies with regard to 
examination of direct immunotoxic effects, since the organs or cells of interest are isolated 
and will not be influenced by effects on other organs (Gennari et al., 2005; Lankveld et al., 
2010). 
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Figure 1. Direct and indirect effects of immunotoxic chemicals on the 
immune system, and possible outcomes (modified from Karras and 
Holsapple (1996)). 
 
1.2.1 Study approaches in immunotoxicology 
The field of immunotoxicology is explored using in vitro and in vivo studies in animals and 
humans (Gennari et al., 2005; Luster et al., 1992; Luster et al., 2005). An important topic in 
research is the three R’s; reduce, refine or replace the use of animals in experimental studies 
(Balls et al., 1995). This is due to animal welfare considerations, the question of relevance to 
risk assessment for humans, as well as economical reasons. The European Community 
regulation REACH (Registration, Evaluation, Authorisation and Restriction of Chemical 
substances), which will require reassessment of thousands of existing chemicals and the use 
of millions of animals (European Commission, 2009), illustrates the need for in vitro methods 
as an alternative to animal models. In vitro methods using human cells may give more 
relevant data for humans compared to animal models regarding direct immunotoxicity. It may 
be a challenge, however, to assess whether the immunotoxic effects observed in vitro are 
biologically relevant (Gennari et al., 2005). Furthermore, the complex interaction between 
immune cells and tissues are difficult to recreate in vitro. Human studies are important for risk 
assessment, but may be time-consuming and expensive, have insufficient exposure data, many 
influencing factors have to be considered, and can not be used for novel substances without a 
Immunotoxic substance 
Nervous 
system 
Endocrine 
system 
Immunosuppression Hypersensitivity Autoimmunity 
Liver 
Immune system 
Direct effect Indirect effect 
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history of human exposure (Descotes, 2006). The four approaches (in vitro and in vivo studies 
in animals and humans) often provide different and supplementary information to a given 
hypothesis (Figure 2) (Adami et al., 2011). 
 
 
Figure 2. Schematic illustration of the 
relationship between the different study 
approaches (modified from Selgrade et al. 
(1995)). 
 
1.3 The developing immune system 
Herbst et al. reported in 1971 that the treatment of women before and during pregnancy with 
stilbestrol (drug to prevent pregnancy complications) was associated with an increased risk of 
vaginal carcinoma of their daughters (Herbst et al., 1971). This was one of the first 
observations in humans of possible effects of prenatal exposure to a chemical (Tomatis, 
1979). In studying the maternal diet during pregnancy, David Barker in 1989 was the first to 
report that the lower the weight of a baby at birth and during infancy, the higher the risk for 
coronary heart disease in later life (Barker et al., 1989). These results led to the ‘Foetal origins 
hypothesis’ or the ‘Barker hypothesis’ which states that coronary heart disease is associated 
with a specific pattern of disproportionate foetal growth that results from foetal undernutrition 
in middle to late gestation (Barker, 1995).  
Many toxicants cross the placenta and reach the developing foetus (Annola et al., 
2008; Annola et al., 2009; Mathiesen et al., 2009; Park et al., 2008), and may be associated 
with increased risk of diseases in later life. Foetal exposure to immunotoxicants is of concern 
since the immune system develops extensively during the foetal stage (Dietert, 2008; 
Animal 
Animal Human 
 
Human 
 
In vivo exposure 
In vitro exposure 
Introduction 
  11
Holsapple et al., 2004; van Loveren and Piersma, 2004; West, 2002). Prenatal immunotoxic 
exposure may result in effects that differ with respect to both the duration of the effect and the 
spectrum of effects compared to exposure in later life (Dietert and Piepenbrink, 2006). 
Furthermore, the foetus may be sensitive to lower doses of immunotoxicants than adults. 
Hence, the prenatal immune system should be viewed as different from that of adults 
regarding risk assessment.  
Since different stages of immune system development may differ in their vulnerability, 
several critical time windows in the foetal stage have been proposed for immunotoxic 
exposure. During the foetal stage, development of the human immune system begins with 
hematopoietic stem cell (HSC) formation, which gives rise to the leukocytes (Holt and Jones, 
2000; Leibnitz, 2005). The HSCs expand and differentiate, and colonize lymphoid organs 
such as the bone marrow and the thymus. Within the thymus, a selection process of T cells 
takes place to eliminate potentially self-reactive cells (Metzger and Anderson, 2011; Murphy 
et al., 2008). This process is very important to avoid the development of autoimmune 
conditions. The foetus exerts Th2 skewed immune responses for protection against toxicity to 
placenta caused by Th1 immune responses (Leibnitz, 2005). At birth, the immune system has 
achieved a considerable level of maturity, but is still not fully developed (Holt and Jones, 
2000; Leibnitz, 2005). The Th1 immune responses will be increasingly expressed, but the Th1 
cytokine IFN- may not reach adult levels until three years of age or later (Leibnitz, 2005; 
Miyawaki et al., 1985). The newborn child has low levels of all self-produced antibodies, 
such as IgG, which does not reach adult levels before 4-6 years of age (Holladay and 
Smialowicz, 2000; Leibnitz, 2005). 
 
1.4 Toxicants in food 
Food items may contain small amounts of toxicants. Dietary toxicants can originate from 
environmental pollution or be formed during food preparation such as baking and broiling, or 
may be life style factors such as alcohol. Table 1 shows examples of 12 dietary toxicants as 
selected within the EU-funded project NewGeneris (Merlo et al., 2009), of which the present 
work was a part (described in section 3.1). In the present work, we have investigated all 12 
substances in an in vitro system, as well as dietary exposure to polychlorinated biphenyls 
(PCBs), dioxins (polychlorinated dibenzo-p-dioxins (PCDDs) and polychlorinated 
dibenzofurans (PCDFs)) and acrylamide in a human study. 
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Table 1. Examples of dietary toxicants as selected within the NewGeneris project (described 
in section 3.1), their chemical classes and dietary sources. 
Chemical class Dietary toxicant Dietary sources 
Acrylamides Monoacrylamide  Generated in plant-derived food 
rich in carbohydrates during heat 
treatment (Mottram et al., 2002; 
Stadler et al., 2002) 
 
Alcohols Ethanol Alcoholic beverages 
 
DNA reactive aldehydes 4-hydroxynonenal (4-HNE) 
 
Malondialdehyde (MDA) 
Generated in food containing 
polyunsaturated fatty acids during 
storage and preparation (Govaris 
et al., 2004; Guillen and 
Goicoechea, 2008) 
 
Heterocyclic amines 
 
2-amino-3-methylimidazo-[4,5-f]quinoline 
(IQ) 
 
2-amino-1-methyl-6-phenylimidazo-[4,5-
b]pyridine (PhIP) 
 
Generated in food rich in proteins 
(meat and fish) during heat 
treatment (Kim and Lee, 2010; Ni 
et al., 2008) 
Mycotoxins Aflatoxins 
 
Deoxynivalenol (DON) 
Fungal toxins that may be found 
in fungus-infected food 
(Schollenberger et al., 2005; 
Thuvander et al., 2001) 
 
Nitrosamines Dimethylnitrosamine (DMNA) Generated in nitrite-containing 
food during e.g. digestion and 
heat treatment (Lijinsky, 1999) 
 
Organochlorines Dioxins 
 
Polychlorinated  
biphenyls (PCBs) 
Environmental pollutants 
contaminating the food chain 
(Charnley and Doull, 2005; 
Domingo and Bocio, 2007) 
 
Polycyclic aromatic 
hydrocarbons 
Benzo[a]pyrene (BaP) Environmental pollutant 
contaminating the food chain, 
generated during food preparation 
(Kazerouni et al., 2001) 
 
1.4.1 PCBs and dioxins 
The main environmental reservoirs of PCBs and dioxins are soils and sediments (Ross, 2004). 
PCBs and dioxins are highly lipophilic and have long half-lives (years) due to resistance to 
degradation processes (Milbrath et al., 2009; Ritter et al., 2011). PCBs and dioxins 
accumulate in adipose tissue as they move up in the food chain, therefore food of animal 
origin is usually the predominant source of exposure in humans. In general, the diet is 
assumed to provide more than 90% of the total human exposure to PCBs and dioxins 
(Domingo and Bocio, 2007; Liem et al., 2000). 
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Dioxins have never been produced intentionally, but are unwanted by-products of 
industrial and combustion processes like burning of waste, chlorine bleaching of paper pulp 
and the manufacturing of organochlorines such as PCBs and some herbicides and pesticides 
(Hites, 2011; WHO, 2010). The first evidence of man-made dioxins is from as early as 1827 
and comes from a German chemical production plant that manufactured washing soda (White 
and Birnbaum, 2009). Dioxins are also produced during natural processes, such as volcanic 
eruptions and forest fires, but human activities have been primarily responsible for the 
environmental contamination by this class of chemicals over the past two centuries (van den 
Berg et al., 1994; White and Birnbaum, 2009).  
Depending on which carbon atoms in the aromatic rings the chlorine atoms are bound 
to (Figure 3 A and B), 210 chemically different congeners of dioxins can be formed, of which 
17 congeners (7 PCDDs and 10 PCDFs) are considered highly toxic (Hites, 2011; van den 
Berg et al., 1994; van den Berg et al., 2006). Most, if not all, immunotoxic and other toxic 
effects of these congeners have been reported to be mediated through the aryl hydrocarbon 
receptor (AhR), a transcription factor which regulates the transcription of several genes 
(Denison et al., 2011; Marshall and Kerkvliet, 2010; Stockinger et al., 2011). Its ligands may 
be both xenobiotics and natural molecules such as the natural photoproduct FICZ (6-
formylindolo[3,2-b]carbazole).  
 
Figure 3. General molecular structure of PCDDs (A), PCDFs (B) and PCBs (C). The 
numbers indicate the possible positions for the chlorine atoms. 
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In contrast to dioxins, PCBs were produced intentionally and were widely used in 
many industrial products since the commercial usage started in 1929 (Ross, 2004). PCBs were 
used particularly as electrical insulation fluids and as heat-exchange fluids due to their 
remarkable electrical insulating properties and their flame resistance. The US Environmental 
Protection Agency (EPA) ultimately banned the manufacture of PCBs in 1979 (US EPA, 
2011), and new usage of PCBs was forbidden in Norway in 1980 (Ministry of the 
environment, 2011). Even today, materials containing PCBs are in use, but there are strict 
regulations on handling and disposal of PCB-containing waste. Thus, the levels of PCBs are 
decreasing worldwide, but still these toxicants are found in humans (Dallaire et al., 2003; 
Llobet et al., 2008; Polder et al., 2008; Ulaszewska et al., 2011). 
There are 209 chemically different PCB congeners depending on which carbon atom 
in the two connected aromatic rings the chlorine atoms are bound to (Figure 3C). Twelve of 
these congeners are considered highly toxic and called dioxin-like PCBs (dl-PCBs) due to 
their similar toxicological properties to the dioxins (van den Berg et al., 2006). The 
comparable toxicological properties of dioxins and dl-PCBs allow the combined exposure to 
be expressed as toxic equivalents (TEQ) (van den Berg et al., 1998; van den Berg et al., 
2006).  
PCB congeners that do not have similar properties to dioxins also exist. These are 
called non-dioxin-like PCBs (ndl-PCBs) (EFSA, 2005). Ndl-PCBs are suggested to be less 
immunotoxic than dioxins and dl-PCBs due to their low binding affinity to the AhR. Most 
epidemiological studies do not differentiate between the exposure to dioxins and dl-PCBs, and 
ndl-PCBs since they may be highly correlated, which complicate the investigation of causal 
relationships. However, immunotoxic effects of ndl-PCBs in animal studies and in in vitro 
studies are reported, which suggest an immunotoxic mechanism independent of AhR 
(Ferrante et al., 2011; Fischer et al., 1998; Levin et al., 2005; Lyche et al., 2004; Lyche et al., 
2006).  
There are well known episodes where animals and humans have accidently been 
exposed to high levels of dioxins and PCBs (Hites, 2011; White and Birnbaum, 2009). The 
herbicide Agent Orange was used by the American military as a defoliant in Vietnam to 
reduce enemy ground cover. Agent Orange was contaminated with 2,3,7,8- 
tetrachlorodibenzo-p-dioxin (TCDD), the dioxin congener regarded as most potent, and 
human exposure was reported to be associated with diseases such as cancer and diabetes 
(Michalek and Pavuk, 2008). In 1968 in Japan, a rice bran oil company’s supplies became 
contaminated with PCBs and dioxins, and in Taiwan in 1979, a similar contamination of rice 
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oil occurred (White and Birnbaum, 2009). The two latter exposures were reported to be 
associated with symptoms such as skin lesions, fatigue, retarded development in children, 
altered reproductive and immunologic function, and cancer (Aoki, 2001; Guo et al., 2004; 
Onozuka et al., 2009). The condition of the exposed humans was called the ‘Yusho’ disease 
in Japan and ‘Yucheng’ disease in Taiwan. 
 Since the developing immune system of the foetus appears to be especially vulnerable 
to toxicant exposure (Holsapple et al., 2004; van Loveren and Piersma, 2004; West, 2002), it 
is of particular concern that the immunotoxicants PCBs and dioxins can cross the placenta and 
reach the foetus (Covaci et al., 2002; Park et al., 2008; Suzuki et al., 2005). Immunotoxic 
effects of prenatal exposure to accidental and high non-accidental levels of PCBs and dioxins 
in humans have been reported (Aoki, 2001; Dallaire et al., 2004; Dallaire et al., 2006; 
Grandjean et al., 2010; Guo et al., 2004; Heilmann et al., 2006). Even though the levels of 
exposure to PCBs and dioxins are decreasing worldwide (Dallaire et al., 2003; Llobet et al., 
2008; Polder et al., 2008; Ulaszewska et al., 2011), effects of prenatal exposure to PCBs and 
dioxins on immunological parameters in humans have been reported also for the general 
population (Glynn et al., 2008; Miyashita et al., 2011; ten Tusscher et al., 2003; Weisglas-
Kuperus et al., 2000; Weisglas-Kuperus et al., 2004). Previous studies on immunotoxic 
effects of pre- and postnatal exposure to PCBs and dioxins have used measurements in 
biological samples such as blood and breast milk, which indicate the body burden of these 
toxicants (Ayotte et al., 2003; Patterson, Jr. et al., 1988; van den Berg et al., 1994). To our 
knowledge, however, immunotoxic effects of PCBs and dioxins from the diet quantified by 
means of a food frequency questionnaire (FFQ) have not been examined. A possible 
advantage of using FFQ data is that the results may indicate more directly than body burden 
(as measured in blood/breast milk) how exposure to toxicants from the maternal diet affects 
the health of the children. This is valuable information to be used in counselling women of 
fertile age regarding their diet.  
1.4.2 Acrylamide 
In 1997, there was a leakage of acrylamide in the Hallandsås tunnel in Sweden (Reynolds, 
2002). Measurements of acrylamide levels in the exposed tunnel workers were compared with 
non-accidently exposed humans, which resulted in the findings that humans in general have 
unexpectedly high levels of acrylamide. Furthermore, it was found that acrylamide was a 
component in tobacco smoke. These findings led to the now confirmed hypothesis that 
acrylamide is generated in food during heat treatment (Hogervorst et al., 2010). Acrylamide is 
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formed in plant-derived food rich in carbohydrates during heat treatment at temperatures 
above 120 °C (Mottram et al., 2002; Stadler et al., 2002; Tareke et al., 2002). Typical food 
items are coffee, crispbread, crisps and deep-fried potatoes. Acrylamide can be generated as a 
result of the Maillard reaction between reducing sugars and amino acids, especially 
asparagine, a major amino acid in potatoes and cereals. Acrylamide is also manufactured by 
the industry, and has since the 1950 been used in the production of polyacrylamides. 
Polyacrylamides are used as flocculants for purifying drinking water and in industrial 
applications such as in the production of textiles and plastics, and grouting (Carere, 2006; 
Hogervorst et al., 2010; Parzefall, 2008). Consequently, non-food exposure to acrylamide 
may exist (Carere, 2006), although the diet is assumed to be the major source of exposure to 
acrylamide for the general non-smoking population.  
Acrylamide is metabolized to a chemically reactive epoxide, glycidamide (Figure 4), 
in a reaction catalyzed by cytochrome P450 2E1 (Hogervorst et al., 2010; Sumner et al., 
1999). Acrylamide binds to proteins, while glycidamide binds to both DNA and proteins 
(Doerge et al., 2005; Tornqvist et al., 2002). Free acrylamide and glycidamide have half-lives 
in the scale of hours (Calleman, 1996; Fennell et al., 2006).  
 
 
    Figure 4. Structures of acrylamide (left) and its major  
    metabolite glycidamide (right).  
 
Carcinogenic, genotoxic, neurotoxic and reproductive toxic properties of acrylamide 
have been reported (Carere, 2006; Hogervorst et al., 2010; Parzefall, 2008). Glycidamide is 
assumed to be responsible for the genotoxic properties of acrylamide and for its carcinogenic 
properties (Paulsson et al., 2001). Information on immunotoxicity of acrylamide is scarce. To 
our knowledge, only Zaidi et al. (1994) have reported on immunotoxic effects of acrylamide 
using a rat model. Acrylamide has been shown to cross the placenta and reach the foetus 
(Annola et al., 2008; Schettgen et al., 2004; Sorgel et al., 2002), but studies on possible 
immunotoxic effects of prenatal exposure to acrylamide have not been published. 
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2 Aims 
 
The overall aim of the work was to investigate the immunotoxic potential of dietary toxicants, 
with a special focus on prenatal exposure to toxicants from the maternal diet. 
 
The specific aims were: 
 
• To explore whether cytokine release from human peripheral blood mononuclear cells in 
an in vitro system can be used as a marker of the immunotoxic properties of 12 selected 
dietary toxicants (Paper I) 
 
• To establish a mother-child birth cohort and employ this cohort to investigate whether 
exposure to acrylamide, PCBs and dioxins from the maternal diet during pregnancy 
increases the risk of immune-related diseases during the three first years of life, and to 
explore whether these toxicants affect immune-related blood parameters in the  
three-year-old children (Papers II and III) 
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3 Subjects and methods 
3.1 The NewGeneris project 
The present work is part of the EU-funded project NewGeneris, which is the acronym for 
‘Newborns and Genotoxic Exposure Risks’ (Merlo et al., 2009). The main aim of 
NewGeneris was to investigate whether maternal exposure to dietary toxicants results in in 
utero exposure and in molecular events in the unborn child, leading to increased risks of 
cancer and immune disorders in childhood. The aims of our workpackage were to develop 
biomarkers of immunotoxic risk based on both in vitro and in vivo studies and to investigate 
possible immunotoxic effects of prenatal exposure to dietary toxicants (Papers II and III). 
Initially, to develop biomarkers, gene expression (transcriptomics) (Hochstenbach et al., 
2010), protein expression (proteomics) and cytokine release (Paper I) were examined in 
peripheral blood mononuclear cells (PBMCs) exposed in vitro to 12 dietary toxicants to find 
candidate biomarker genes and proteins. The candidate biomarkers were then investigated in a 
birth cohort called BraMat. The biomarkers will finally be applied on several European birth 
cohorts to achieve the main aim of the NewGeneris project.  
 
3.2 Subjects 
In the in vitro study (Paper I), healthy non-smoking Caucasian males (n=25) and females 
(n=35) (20-35 years of age) were used as blood donors. ‘Healthy’ was defined as absence of 
self-reported infections, chronic diseases like autoimmune disorders or use of medication at 
the time of blood sampling.  
For the birth cohort BraMat (Papers II and III), invitations to participate were sent by 
regular mail to all pregnant women already enrolled in the Norwegian Mother and Child 
Cohort Study (MoBa) (April 2007 - March 2008), and who were scheduled to give birth at 
Oslo University Hospital Ullevål or Akershus University Hospital (25% participation rate). 
MoBa is a prospective population-based pregnancy cohort study conducted by the Norwegian 
Institute of Public Health, including 108 000 children born between 1999 - 2008 from all over 
the country (38.5% participation rate) (Magnus et al., 2006). Invitations to the BraMat birth 
cohort were sent in week 37 of gestation, thus only infants that had experienced a full term 
pregnancy (37th - 42nd week of gestation) were included. There were no plurality births. 
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Exclusion criteria for the BraMat cohort were autoimmune diseases of the mother and use of 
steroids, anti-inflammatory drugs or epileptic drugs during pregnancy.  
  
3.3 In vitro study 
The design of the in vitro study is shown in Figure 5. The in vitro methods are described in 
more detail in Paper I. In short, PBMCs were isolated from venous blood of adults. The 12 
selected substances (Table 1; PCBs: PCB-153; dioxins: TCDD) were classified into 
immunotoxic and non-immunotoxic substances based on published in vivo data. The 
concentrations of these substances and the exposure duration used in the experiments were 
determined based on preliminary experiments (described in Paper I). To select the 
concentration ranges, we first wanted to determine the concentrations causing 10% 
cytotoxicity. Since all concentrations tested caused <10% cytotoxicity based on the trypan 
blue exclusion technique, other criteria were used to select the concentration ranges 
(described in Paper I). The cells were exposed to three concentrations (tenfold dilution series) 
of each of the 12 substances. Each cell culture contained 10% freshly made S9-mix (human 
liver S9-fraction and co-factors) for biotransformation of the substances to mimic the process 
after peroral exposure in the in vivo situation. The cell cultures were incubated for 20 hours at 
37C in a humidified atmosphere with 5% CO2. The tubes were kept at a 20° angle to avoid 
formation of a dense cell pellet. For each substance, cells from four donors were individually 
exposed to all three concentrations of the substance and its respective solvent.  
 
 
 
Figure 5. The design of the in vitro study.  
PBMC 
12 substances 
3 concentrations 
Human liver S9 fraction 
20 hours 
 
 
 
PBMC 
Fresh culture medium 
PHA 
48 hours 
 
Proliferation 
Cytokine release: 
IL -1, IL-2, IL-4, IL-10, 
IL-13, IL-17, G-CSF,  
IFN- and TNF- 
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After exposure, the substances and S9-mix were removed from the cell cultures. The 
cells were resuspended in culture medium containing 10 μg/ml of the mitogen 
phytohemagglutinin (PHA; Sigma-Aldrich, St.Louis, MO, USA) and incubated for 48 hours 
at 37C in a humidified atmosphere with 5% CO2.  
Mitogen-induced proliferation was determined using a colorimetric immunoassay 
based on BrdU incorporation during DNA synthesis (Roche Diagnostics GmbH, Penzberg, 
Germany). In the supernatants, nine cytokines IL-1, IL-2, IL-4, IL-10, IL-13, IL-17, G-CSF, 
IFN- and TNF- (Table 2) were quantified using a Bio-Plex Human Cytokine Assay (Bio 
Rad, Hercules, CA, USA). These cytokines were selected to reflect different types of immune 
responses such as Th1, Th2, regulatory and proinflammatory responses and to enable the use 
of a single dilution (1:2) to determine cytokine release (described in Paper I). Due to donor 
variation of mitogen-induced cytokine release and proliferation in the solvent controls, the 
parameters were expressed relative to the corresponding solvent control. 
 
 
Table 2. The nine selected cytokines, their producer cells and their effects (Murphy et al., 
2008; Oppenheim et al., 2001). 
Cytokine Producer cells Effects 
IL -1 Macrophages, epithelial cells Fever, T cell activation, macrophage activation 
IL-2 T cells Proliferation, differentiation and survival of T cells and NK 
cells 
IL-4 T cells, mast cells, basophils Regulation of IgE and IgG1 (mice) production, induces 
differentiation into Th2 cells 
IL-10 Monocytes, T cells Suppression of immune responses, but possesses also 
stimulatory activities 
IL-13 Th2 cells, mast cells,  
NK cells 
Regulation of IgE secretion by B cells, modulation of Th2 
cell development, suppression of inflammatory responses 
due to regulation of macrophage function, plays a central 
role in Th2 responses 
IL-17 T cells Induces production of several proinflammatory and 
hematopoietic bioactive molecules by stromal cells 
IFN- T cells, NK cells Macrophage activation, increased expression of MHC 
molecules and antigen presenting components, Ig class 
switching, suppresses Th2 responses 
G-CSF Fibroblasts, monocytes, 
endothelial cells 
Stimulates neutrophil development and differentiation 
TNF- Macrophages, NK cells,  
T cells 
Promotes inflammation and endothelial activation 
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3.4 BraMat study design 
We used a prospective cohort study design (Figure 6). Maternal intake of the toxicants during 
the first four months of pregnancy was calculated using a food frequency questionnaire 
(FFQ). The children were followed annually during the three first years of life using 
questionnaires covering immune-related health outcomes. Furthermore, at three years of age, 
immune-related blood parameters were examined: concentrations of allergen specific IgE 
antibodies, vaccine antibody levels and immunophenotype data.  
 
 
Figure 6. The study design for the BraMat cohort. 
 
3.5 Questionnaires and health outcomes 
When the children in the BraMat cohort were one, two and three years of age, a questionnaire 
was sent to the mothers (Appendix A-D). The mothers could either fill in the questionnaire 
and return it by regular mail, or give the answers by a telephone interview. The questionnaire 
covered topics for the last year related to the child’s infectious diseases, allergy, asthma and 
other chronic diseases and the use of medications. Concerning infectious diseases, the 
mothers were asked if the child had experienced the following diseases/complaints and the 
number of episodes: colds and other upper respiratory tract infections, otitis media, 
pneumonia, gastroenteritis with vomiting or diarrhoea and urinary tract infection. The mothers 
were also asked if the child had experienced any childhood diseases, such as chicken pox and 
exanthema subitum (roseola infantum). Concerning allergy, asthma and other chronic 
diseases, the mothers were asked: ‘Has the child been diagnosed with asthma, asthma-
bronchitis or bronchial hyperreactivity by a doctor?’ (Bronchial hyperreactivity was not 
2nd year: 
Questionnaire 
1st year: 
Questionnaire 
Birth
0-4th pregnancy months: 
Maternal intake of 
toxicants calculated  
using FFQ 
3rd year: 
Questionnaire  
Blood parameters 
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included in the questionnaire for the first year.) ‘Has the child had periods of more than 10 
days with dry cough, chest tightness or wheeze, or shortness of breath? Has the child had 
eczema or itching in the face or at joints (e.g. the groin, hollow of the knee, ankle, elbow and 
wrist)? Has the child been diagnosed with atopic dermatitis by a doctor? Has the child been 
diagnosed with allergy by a doctor? Has the child any other chronic disease?’ Data for the 
first year (Paper II), cumulative data (0-3 years of age, Paper III) and data for the last year 
only (2-3 years of age, Paper III) were used to examine possible associations between prenatal 
toxicant exposure and health outcomes during early childhood. 
 In addition to BraMat questionnaires, potential confounding variables were extracted 
from MoBa questionnaires filled in by the mothers during pregnancy (~15th and 30th week of 
gestation) and about six months after birth. Birth-related information was extracted from the 
Medical Birth Registry of Norway (MBRN). 
 
3.6 Dietary exposure assessment 
Of the 12 substances selected within the project NewGeneris, alcohol, acrylamide, PCBs and 
dioxins were examined further in the BraMat cohort due to availability of exposure data and a 
wish to include both persistent and non-persistent toxicants. Concerning alcohol, only 25 
(12.2%) of the mothers reported consuming alcoholic beverages during pregnancy, regarded 
to be too low a number to perform statistical analyses.  
Maternal intake of the dietary toxicants polychlorinated biphenyls (PCBs), 
polychlorinated dibenzo-p-dioxins/dibenzofurans (PCDDs/PCDFs or dioxins) and acrylamide 
was calculated from a validated FFQ used in MoBa (The Norwegian Mother and Child 
Cohort Study, 2011a; The Norwegian Mother and Child Cohort Study, 2011b). Description 
and validation of the FFQ is reported elsewhere (Brantsaeter et al., 2008a; Meltzer et al., 
2008). The method for calculating dietary exposure to acrylamide, PCBs and dioxins has been 
described in Brantsaeter et al. (2008b) and Kvalem et al. (2009), respectively. As described in 
section 1.4.1, PCBs and dioxins can be divided into two groups according to their 
toxicological properties: 1) dioxins and dioxin-like PCBs (dl-PCBs) and 2) non-dioxin-like 
PCBs (ndl-PCBs). The most toxic congeners were included in the TEQ calculations for 
dioxins and dl-PCBs: all 17 of the 2,3,7,8-substituted PCDD/PCDFs; non-ortho-substituted 
PCBs: PCB-77, -81, -126 and -169; mono-ortho-substituted PCBs: PCB-105, -114, -118, -
123, -156, -157, -167 and -189. For ndl-PCBs, the sum of exposure to PCB-28, -52, -101, -
138, -153 and -180 was used. The exposure was expressed relative to the mother’s self-
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reported body weight (bw) before pregnancy, thus the exposure to dioxins and dl-PCBs was 
expressed as pg TEQ/kg bw/day, exposure to ndl-PCBs as ng/kg bw/day and acrylamide as 
g/kg bw/day.  
  
3.7 Blood analyses 
Blood sampling and analyses are described in more detail in Paper III. In short, venous blood 
was collected from the three-year-old children either at their doctor’s office, at home by a 
clinical laboratory technician or at a commercial laboratory (Fürst Medical Laboratory, Oslo).  
Levels of specific IgG antibodies to measles, rubella, tetanus toxoid, pneumococcal 
polysaccharides and Haemophilus influenzae type b (Hib) were determined in the sera of the 
children using ELISA techniques. 
Allergen-specific IgE antibodies were analysed in the sera of the children using 
ImmunoCAP Phadiatop® Infant (Phadia AB, Uppsala, Sweden) comprising 11 allergens 
selected to be relevant for young children (house dust mite, cat, dog, hen’s egg, cow’s milk, 
peanut, shrimp, timothy, birch, ragweed and wall pellitory (Parietaria judaica)). Sera from 
the children found to be sensitized using Phadiatop Infant were analysed for specific IgE 
antibodies to the ‘individual’ allergen preparations from house dust mite, cat, dog, hen’s egg, 
cow’s milk, peanut, timothy and birch. Determination of the serum concentration of specific 
IgE to allergens is used to diagnose allergic sensitization. A positive test does therefore not 
necessarily mean that the tested individual has an allergic disease (Sicherer and Sampson, 
2010).  
Immunophenotyping using flow cytometry was performed on whole blood of the 
children within 24 hours after blood collection according to the protocol of the manufacturer 
(BD, Franklin Lakes, NJ, USA). The percentage and absolute number of monocytes (CD14+) 
and the following lymphocyte subsets were determined: T cells (CD3+), T-helper cells 
(CD3+CD4+), cytotoxic T cells (CD3+CD8+), B cells (CD19+), natural killer (NK) cells 
(CD16+CD56+) and natural killer T cells (CD3+CD16+CD56+). Furthermore, the percentage 
of regulatory T cells of CD4+cells were determined (CD4+CD25highCD127low).  
 
3.8 Statistical analyses 
Principal component analysis (PCA) with the log-transformed values of the in vitro cytokine 
release data relative to solvent control was performed to investigate clustering of the cell 
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cultures based on effects on cytokine release (Genedata Expressionist® software). To enable 
exclusion of cytotoxic concentrations, proliferation data were visualised (colour coded) in a 
PCA plot to examine if proliferation was in concordance with the clustering (Paper I). 
Furthermore, in vivo-based (literature) classification of the immunotoxic potential of the 
substances was visualised (colour coded) in a PCA plot to investigate if all cytokines 
combined could be used to distinguish the immunotoxic from the non-immunotoxic 
substances. 
 A multivariate random effects model (mixed model) was applied to assess the 
influence of in vitro exposure to the 12 substances on the subsequent mitogen-stimulated 
release of each of the nine cytokines and the proliferation. One analysis was performed per 
substance. A nested model was used since one donor was exposed to all three concentrations 
of one substance resulting in dependent variables. To examine the associations, the Cook’s D 
and the multivariate DfFits statistics (Belsley et al., 1980) as well as the Covtrace and the 
Covratio statistics were used. The post hoc test Simes’ procedure was used to adjust for 
multiple testing. The analyses were performed in Statistical Analysis System (SAS, Cary, NC, 
USA) version 9.1.3. A change in cytokine release relative to the corresponding solvent control 
was considered to be statistically significant if the value 1 was not included in the 95% 
confidence interval. 
 In Papers II and III, logistic regression analyses were applied to assess the influence of 
exposure on the different binary health outcomes for the children. The exposure to the dietary 
toxicants were categorised using the 80th percentile to compare the highest exposed children, 
who constituted the upper tail of the exposure distribution, with the remaining children (80th 
percentile and <80th percentile, respectively). If no statistically significant associations were 
found, also the continuous exposure variables were examined since the use of continuous 
variables usually increase the statistical power compared to categorised variables. For eczema 
in the first year of life, the exposure to the dietary toxicants was categorised using the tertiles 
due to apparently nonlinear associations (the reference category was the lowest exposure 
category). Highly correlated variables (correlation coefficients 0.7) were not included in the 
same multivariate analysis. Separate multivariate analyses were therefore performed for the 
dietary toxicants dioxins and dl-PCBs, and ndl-PCBs (b = 0.81, p<0.001). Since parity, 
previous breast-feeding and number of older siblings/children living together with the child 
were also highly correlated (b ~ 0.9, p<0.001), only parity was included in the multivariate 
analyses. The criterion for inclusion of potential confounding variables in the multivariate 
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regression analyses was p<0.250 in bivariate analysis. The manual backward deletion method 
was used starting with all included variables in the model. At each deletion step, the least 
significant variable in the multivariate model was manually removed until only statistically 
significant (p<0.05) variables remained in the model. Hosmer-Lemeshow test, Cook’s D and 
residuals were used to investigate the robustness of the multivariate logistic regression 
models.  
For the outcome variables ‘numbers of upper respiratory tract infections’ (URTI) and 
‘numbers of episodes of gastroenteritis’, linear regression analyses were applied. The variable 
‘numbers of upper respiratory tract infections’ was ln-transformed (ln (URTI+1)) except for 
the data for the first year of life. For the transformed variables, the reported results are back-
transformed values (ratio of effect). The exposure variables and the inclusion criterion for 
potential confounding variables in the multivariate analyses were the same as for logistic 
regression analyses (described above). Cook’s D, Leverage values and residuals were used to 
investigate the robustness of the multivariate linear regression models.  
The immune-related blood parameters were investigated by linear and logistic 
regression analyses. Due to small sample size, ln-transformed exposure variables were used in 
the statistical analyses to avoid results being strongly influenced by only a few observations. 
The outcome variable was ln-transformed if necessary to fulfil the criteria of normally 
distributed residuals. For the transformed outcome variables, back-transformed values are 
reported. Multivariate regression analyses were performed as described above. 
Results of the logistic and linear regression analyses were considered statistically 
significant at p<0.05. The statistical analyses were performed using the statistical software 
PASW Statistics 17 (SPSS Inc., Chicago, IL, USA).  
 
3.9 Ethical issues 
The study was approved by the Norwegian Regional Committee for Medical and Health 
Research Ethics and the Data Inspectorate. All blood donors and mothers enrolled in the 
BraMat cohort gave their written informed consent. 
 To recruit pregnant mothers to the BraMat cohort, the mothers received a brochure 
presenting the study, including the information that potential harmful substances in the 
maternal diet may exert adverse effects resulting in increased risk of immune-related diseases 
in the child. This information can make the parents worried, and in the brochure, we therefore 
focused on that the BraMat cohort was established to assure that dietary exposure to the 
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substances of investigation is associated with no or low risk of immune-related diseases. The 
parents also received contact information to persons who could answer possible questions.  
Mothers with family relations or co-workers to personnel involved in the project were 
excluded. It was ensured that the mothers who chose to give the answer on the questionnaires 
by a telephone interview, were interviewed by a person unknown to them. 
Regarding blood sampling, qualified health personnel were used to reduce 
unnecessary discomfort for the three-year-old children. Individual results of blood analyses 
were given to parents on request. Only results with diagnostic values (IgE-test) were given to 
the parents, followed by a detailed explanation of the test result.  
The blood samples and the questionnaires were labelled with an ID-code, and the ID-
code was also used in the data files. Only a few persons have access to the file (key-file) 
containing the link between ID-codes and personal data. The key-file is stored in a secure 
zone at the institute’s server.
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4 Results 
4.1 In vitro exposure and cytokine release 
For some concentrations of the 12 substances, the proliferation and the release of most, if 
not all, nine cytokines were strongly reduced relative to solvent control, which suggests 
cytotoxic effects. These concentrations were excluded in further analyses based on 
clustering of the cell cultures in a PCA plot (described in section 3.8). After exclusion, all 
substances significantly affected the cytokine release relative to solvent control for one or 
more cytokines, and the cytokine release patterns differed depending on substance and 
concentration (Paper I). To investigate if it was possible to distinguish immunotoxic from 
non-immunotoxic substances using in vitro cytokine release, the significant effects on 
release of each cytokine were examined separately and in combinations of cytokines. 
However, we did not find any common effect pattern on cytokine release for either the 
immunotoxic or the non-immunotoxic substances. Neither when using PCA, the release of 
the nine selected cytokines could distinguish the immunotoxic from the non-immunotoxic 
substances.  
 
4.2 Prenatal exposure and immunotoxicity in children 
BraMat questionnaires were received for 195 (95%), 184 (90%) and 180 (88%) of the 205 
children for the first, second and third year, respectively. All three questionnaires were 
received for 162 (79%) children. Since few children had experienced pneumonia, urinary 
tract infection and ‘other chronic diseases’, statistical analyses were not performed on these 
health outcomes. For the same reason, analyses for the health outcomes asthma and allergy 
diagnosed by a doctor and numbers of episodes of gastroenteritis were performed on 
cumulative data (0-3 years of age) only. Furthermore, analyses on frequency of childhood 
diseases were performed on first year data and on cumulative data. All other health 
outcomes were investigated for first year, third year and cumulative data. 
Data on health outcomes and potential confounders for some of the children were 
missing since some of the questionnaires were incomplete. Exposure data (intake/bw) could 
not be calculated for five of the mothers since the body weight was missing, and they were 
therefore excluded from the statistical analyses. The calculated maternal dietary intake of 
Results 
  28 
dioxins and dl-PCBs, ndl-PCBs and acrylamide is presented in Table 3, and the dietary 
sources of exposure to the toxicants in the BraMat cohort are shown in Figure 7.  
 
 
Table 3. The calculated dietary intake of ndl-PCBs, dioxins and dl-PCBs, and 
acrylamide for the mothers in the BraMat cohort (n=200).  
Dietary toxicant     Mediana Min Max IQR 80th P 
Ndl-PCBs (ng/kg bw/day) b   2.59 0.53 30.12 1.80-4.09 4.37 
Dioxins and dl-PCBs (pg TEQ/kg bw/day) c 0.58 0.15 3.07 0.45-0.81 0.90 
Acrylamide (g/kg bw/day)   0.56 0.07 2.05 0.41-0.72 0.79 
IQR: interquartile range; P: percentile 
a The median values are presented since the data were not normally distributed. 
b PCB-28, -52, -101, -138, -153 and -180. 
c All 17 of the 2,3,7,8-substituted PCDD/PCDFs; non-ortho-substituted PCBs: PCB-77, -81, -126 
and -169; mono-ortho-substituted PCBs: PCB-105, -114, -118, -123, -156, -157, -167 and -189. 
 
 
 
Seafood was a major source of exposure to dioxins and dl-PCBs, and ndl-PCBs, of which 
fat fish such as salmon, trout, mackerel and herring was the most important. Other dietary 
sources such as cereals, eggs (including seagull eggs), milk and dietary products also 
contributed to the exposure to these toxicants. For acrylamide, important sources were 
crispbread, crisps and other snacks. Coffee is usually an important source of acrylamide 
exposure (JECFA, 2005), but not for the pregnant women in the BraMat cohort. One reason 
may be the recommendations of low coffee consumption during pregnancy by the 
Norwegian authorities (Norwegian food safety authority, 2011a).  
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Figure 7. The dietary sources of exposure to dioxins and dl-PCBs (A), ndl-PCBs (B) and 
acrylamide (C) for the mothers in the BraMat cohort (n=205). Other: dietary supplements, 
spices and baking powder etc.  
 
4.2.1 PCBs and dioxins – health outcomes 
Results of bivariate analyses and statistically significant multivariate analyses are shown in 
Table 4-6. Prenatal dietary exposure to dioxins and dl-PCBs, and ndl-PCBs was 
significantly associated with an increased risk of wheeze (periods of more than 10 days 
with dry cough, chest tightness or wheeze, or shortness of breath) during the first year of 
life (Paper II) and the three first years of life (Paper III), whereas no associations were 
found for the third year only (Paper III).  
Regarding infections, prenatal dietary exposure to dioxins and dl-PCBs, and ndl-
PCBs was significantly associated with increased numbers of upper respiratory tract 
infections up to three years of age (Papers II and III). Prenatal exposure to dioxins and dl-
PCBs, and ndl-PCBs was also associated with an increased risk of the childhood disease 
exanthema subitum during the first year of life (Paper II). Furthermore, prenatal exposure 
to dioxins and dl-PCBs, and ndl-PCBs was associated with increased numbers of episodes 
A B 
C White breadWholemeal bread
Nut spread
Cereal, porridge 
Cornflakes
Dairy products, fatty 
Yoghurt
Non-alcoholic beer
Beer
Coffee
Decaffeinated coffee
Poultry
Fish, fish products
Pizza, taco
Potatoes
Potatoes, fried 
Dried fruit
Dairy products, desserts 
Waffles, pancakes 
Buns
Cakes
Chocolate
Toffee, sweets 
Crisp
Crispbread
Caffè latte
Cookies
Snacks other than crisp 
Milk and dairy products 
Egg 
Meat
Seafood 
Cereals 
Vegetables 
Fruits, berries, and nuts 
Fat
Sweets and snacks 
Beverage 
Other
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of gastroenteritis in the three first years of life (Paper III). However, the associations with 
numbers of episodes of gastroenteritis were not robust as indicated by the residuals and 
Cook’s D. 
Increased prenatal exposure to dioxins and dl-PCBs, and ndl-PCBs was also 
associated with a decreased risk of eczema or itching for the first year of life in bivariate 
logistic regression analyses when the levels of exposure to dietary toxicants were 
categorised using the tertiles (Table 5). However, when adjusted for maternal BMI in the 
final models, the associations were not statistically significant (ndl-PCBs: OR (95% CI) p-
value; 1st vs 2nd tertile: 0.45 (0.18, 1.14) 0.091; 1st vs 3rd tertile: 0.83 (0.36, 1.91) 0.668; 
dioxins and dl-PCBs: 1st vs 2nd tertile: 0.49 (0.20, 1.22) 0.127; 1st vs 3rd tertile: 0.76 (0.32, 
1.78) 0.521). Finally, prenatal exposure to ndl-PCBs was associated with an increased risk 
of doctor diagnosed allergy up to three years of age (Table 6), but the association was not 
robust as indicated by residuals and Cook’s D (Paper III). 
4.2.2 PCBs and dioxins – blood parameters at three years of age 
Blood was collected from 112 (56%) of the 205 children. Due to logistic challenges, 
immunophenotyping and regulatory T cell assessment could only be performed for 81 and 
78 samples, respectively. Vaccine-induced antibody levels and concentrations of allergen 
specific IgE antibodies were measured in 111 samples (110 samples for rubella and measles 
antibodies). There were no statistically significant differences with regard to frequency of 
health outcomes in children giving and not giving a blood sample at three years of age 
(results not shown). 
No significant associations were found between prenatal exposure to PCBs and 
dioxins and the levels of different subpopulations of leukocytes in peripheral blood at three 
years of age (Paper III). Regarding vaccine-induced antibody levels, prenatal exposure to 
ndl-PCBs, and dioxins and dl-PCBs was associated with reduced levels of anti-measles 
antibodies in multivariate analyses (ndl-PCBs:  (95% CI) p-value; -0.12 (-0.23, -0.01) 
0.032; dioxin and dl-PCBs: -0.15 (-0.29, -0.01) 0.036). None of the other vaccine-induced 
antibody levels were significantly associated with prenatal exposure to dioxins and dl-
PCBs, and ndl-PCBs (Paper III).  
Twenty-three of 111 (20.7 %) children were found to be sensitized using Phadiatop® 
Infant. In bivariate logistic regression analyses, no significant associations were found 
between prenatal exposure to dioxins and dl-PCBs, and ndl-PCBs and sensitization (Paper 
III). Furthermore, when the positive sera were analysed for specific IgE antibodies to the 
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‘individual’ allergen preparations, 15 out of the 23 children were found to be sensitized to 
at least one of the food allergens tested, nine to at least one of the respiratory allergens 
tested, whereas five children were not sensitized to any of the ‘individual’ allergen 
preparations tested.  
4.2.5 Acrylamide 
No significant associations were found between prenatal dietary exposure to acrylamide 
and the investigated immune-related health outcomes or blood parameters at any age 
(Papers II and III). 
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5 Methodological considerations 
5.1 In vitro assay 
The overall aim of the work was to investigate the immunotoxic potential of dietary toxicants, 
with special focus on prenatal exposure to toxicants from the maternal diet. Therefore, in 
principle, cord blood would have been the best source of mononuclear cells (CBMC). Due to 
low volumes of cord blood available in the present work, PBMCs from adults were used to 
obtain sufficient amounts of mononuclear cells. Since CBMCs are immature and may 
therefore respond differently to exposure than PBMCs from adults (Bessler et al., 2002; 
Bessler et al., 2007; Goldberg et al., 2008), the possibility of different effects of exposure to 
the 12 investigated substances for the CBMCs and PBMCs cannot be excluded.  
We did not include more than four donors per substance since such an in vitro 
screening assay should be practically feasible with regard to donor recruitment and amount of 
labour. Cells from both genders were used for all substances due to possible gender 
differences in the response to toxicant exposure (Aldridge et al., 2003). Due to individual 
variation, including possible gender differences, and low statistical power, some immunotoxic 
effects may not have been detected in our in vitro assay.  
Human liver S9-fraction was used in all cell cultures to allow biotransformation of the 
12 substances since it may be the metabolites of a substance that cause the adverse effects 
after peroral exposure in vivo (Coecke et al., 2006). Effects of BaP on gene expression 
(mRNA) were found to be weaker in cultures without S9-fraction in our in vitro system, 
which suggests that BaP was successfully biotransformed by the enzymes in the S9-fraction 
(Hochstenbach et al., 2010). This may suggest that the enzymes were able to exert 
biotransformation under our cell culture conditions. In preliminary experiments, however, the 
S9-fraction appeared to influence cytokine release and proliferation also in the solvent 
controls (results not shown). Independent of whether biotransformation was necessary for the 
substance to exert their effects or not, S9-fraction was added to all cell cultures to minimize 
cell culture variations.  
All 12 substances selected within the NewGeneris project were included in the in vitro 
study. Of these, four were classified as non-immunotoxic substances and were used to 
investigate whether it was possible to distinguish immunotoxic from non-immunotoxic 
substances. Since all the substances were classified into carcinogenic and/or immunotoxic 
substances, and the solvent controls were used in the calculation of the results of the cytokine 
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release and the proliferation, an improvement might have been to include a substance with no 
known effects as a negative control.   
Viability was measured initially using the trypan blue exclusion technique, which is 
based on the principle that live cells possess intact cell membranes that exclude the dye trypan 
blue, whereas dead cells do not (Stober, 1997). This technique has limitations due to the 
indirect measure of viability based on cell membrane integrity, and the subjective assessment 
of viability (dye exclusion). Still, this method was selected since the use of objective and less 
time-consuming assays (Lactate dehydrogenase (LDH) and Alamar blue) were found not to 
be suitable due to interference by the S9-mix in the cell cultures. Trypan blue uptake, 
however, was for four of the substances compared with the objective method propidium 
iodide uptake determined by flow cytometry. The results from the two methods were similar, 
indicating that subjective interpretation was not a problem in the present work. The viability 
determined by trypan blue was >90% after exposure to all concentrations of the substances. 
Still, for some of the concentrations used, proliferation and release of most, if not all, nine 
cytokines were strongly inhibited. The viability of the cells may be affected, such as cell 
functions, even if its membrane integrity is maintained as measured by trypan blue exclusion 
technique (Stober, 1997). The observed inhibition may therefore suggest cytotoxic effects, 
and these concentrations were excluded (described in section 3.8).  
 
5.2 Questionnaires 
The potential selection bias (i.e. a systematic error due to the procedures used to select 
subjects and from factors that influence study participation which result in a mistaken 
observed association (Gordis, 2000)) in MoBa due to self-selection of participation has been 
evaluated by Nilsen et al. (2009). Eight well-known exposure-outcome associations were 
estimated separately for MoBa participants and the total population, such as prenatal smoking 
and low birth weight (<2500g), chronic hypertension and gestational diabetes and parity and 
pre-eclampsia. No statistically significant relative differences in association measures were 
found between MoBa participants and the total population, and the authors suggested that the 
results of MoBa are not influenced by selection bias (Nilsen et al., 2009). Selection bias due 
to the low recruitment rate from MoBa into the BraMat cohort, however, cannot be excluded.  
 Calculation of the dietary exposure using FFQ may give inaccurate exposure estimates 
due to possible misreporting of the dietary intake, the use of standard portion sizes and the use 
of expected representative concentrations of toxicants for specific food items. However, the 
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FFQ used in the present work has been well validated (Brantsaeter et al., 2008a), and 
calculated intake of PCBs and dioxins from the diet has been found to be correlated with 
blood concentrations (e.g. dioxins and dl-PCBs: 	=0.34, p=0.017), and calculated intake of 
acrylamide correlated with concentrations of acrylamide metabolites in urine (acrylamide: 
	=0.26, p=0.005) (Brantsaeter et al., 2008b; Kvalem et al., 2009). Even though, in general, 
dietary intake over a certain period and concentrations in biological samples are different 
measures of exposure and should be compared with caution, the correlations previously 
reported suggest that the calculated intake of the toxicants reflects the exposure from the diet.  
The mothers had the choice of returning the BraMat questionnaire by regular mail or 
to answer the questionnaire by telephone interview. To avoid differences in the answers for 
the two answering opportunities, the interviewers were instructed to ask the questions as 
written in the questionnaires and not to discuss the answers. No statistically significant 
differences were found with regard to frequency of health outcomes when comparing the 
written questionnaires and the telephone interviews in the one-year follow-up in the BraMat 
cohort (Paper II).  
 
5.3 Blood parameters 
Antibody responses to vaccines were included as a measure of immune function. Vaccine 
responses are a promising tool in immunotoxicity testing, including developmental 
immunotoxicology studies (Luster et al., 2005; van Loveren et al., 2001). It is unlikely that 
toxicants have the intrinsic capability to disrupt completely the responses to vaccines, but 
reduced levels of vaccine-induced antibodies may indicate a capacity of immunosuppression.  
In the present work, it was important to measure the antibody levels at corresponding times 
with regard to vaccinations for all children to reduce variability in the phase of the immune 
responses to vaccines. The dates of vaccinations were not available, however, and the time 
intervals between vaccination and blood sampling could therefore not be adjusted for in the 
multivariate analyses. The five selected vaccines in the Norwegian Childhood Vaccination 
Program are generally administered previous to 16 months of age, whereas the blood samples 
in the present work were collected at about three years of age (33-43 months). Thus, 
variations in vaccination responses due to differences in time intervals are assumed to be of 
less importance. Two viral (attenuated measles and rubella), one bacterial toxin (tetanus 
toxoid) and two bacterial polysaccharide-protein conjugate vaccines (pneumococcus and 
Haemophilus influenzae type b (Hib)) were selected. Different vaccines, including adjuvants, 
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may stimulate distinct components of the immune system resulting in vaccine-dependent 
differences in the effects of a toxicant. In addition, exposure to different toxicants may exert 
different effects on the various vaccine responses.  
Immunophenotyping using flow cytometry may be useful in diagnosing individuals 
with severe immunodeficiency disorders such as HIV, but the method has not always been 
successful in identifying minor immunodeficiencies in humans, including those associated 
with toxicant exposures (Luster et al., 2005). However, immunophenotyping was performed 
in peripheral blood sampled at three years of age, since at the population level 
immunophenotyping may be valuable to detect immunotoxic effects (Luster et al., 2005). If 
statistically significant associations between exposure and absolute or relative numbers of 
different leukocyte populations are found, the associations may be of importance even though 
the absolute or relative numbers are within normal reported ranges and thus difficult to 
interpret with regard to biological significance. The numbers of cells in tissues, however, may 
not be reflected in blood. Furthermore, the absolute or relative numbers of leukocyte 
populations are only indirect measures of immune function which is more decisive.  
  
5.4 Statistical analyses 
Based on other studies reporting associations between prenatal exposure to PCBs and dioxins 
and immune-related endpoints (Dallaire et al., 2004; ten Tusscher et al., 2003; Weisglas-
Kuperus et al., 1995; Weisglas-Kuperus et al., 2000; Weisglas-Kuperus et al., 2004), a 
follow-up study including 200 participants were considered to have sufficient statistical power 
to reveal the strongest associations. A study with 200 participants may, however, have too low 
statistical power to be able to conclude on negative findings, and it may be difficult to 
properly assess and adjust for all possible confounding factors. To achieve a precise effect 
estimate, it is possible that all known potential confounding factors have to be included and 
properly adjusted for in the final models (Budtz-Jorgensen et al., 2007). In the present work, 
however, potential confounding variables not significant in the multivariate analyses were 
excluded using backward elimination method to gain statistical power. 
On count data, Poisson or negative binomial regression analyses are often used due to 
the distribution of the data, while linear regression analyses are most appropriate if the 
data/residuals are normally distributed. The latter was not the case for numbers of upper 
respiratory tract infections (0-3 and 2-3 years of age). Neither did these data fulfil the 
assumption of the Poisson regression analysis (equal mean and variance of the Poisson 
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distribution). The negative binomial regression allows data with a greater variance, as in the 
present work. However, the results of linear regression analyses with ln-transformed data 
using the statistical software SPSS were similar to negative binominal regression analyses 
using the statistical software Stata. Linear regression analyses were therefore chosen for 
practical reasons. 
 
 
Discussion 
  41
6 Discussion 
6.1 Immunotoxicity of dietary toxicants in vitro 
As a result of today’s search for alternative methods to the use of animals in toxicity testing of 
chemicals (Balls et al., 1995), many studies have been performed to establish in vitro assays 
to predict in vivo effects of substances on the immune system (Carfi' et al., 2007; Fischer et 
al., 2011; Galbiati et al., 2010; Hymery et al., 2006; Koeper and Vohr, 2009; Langezaal et al., 
2001; Lankveld et al., 2010; Lebrec et al., 1995; Ringerike et al., 2005; Wagner et al., 2006). 
Assessment of cytokine release from leukocytes in vitro has been proposed to be a useful 
method to examine immunotoxic effects of substances (Corsini and House, 2010; Gennari et 
al., 2005; House, 1999). Since different substances act via different mechanisms, several 
cytokines may have to be analyzed to detect immunotoxicity (Ringerike et al., 2005). In the 
present work, we explored whether effects on the release of nine selected cytokines from 
human PBMCs in an in vitro system could be used as a marker of the immunotoxic properties 
of dietary toxicants. However, the effects of the 12 selected substances on in vitro cytokine 
release did not reflect the in vivo-based classification of their immunotoxic potential. None of 
the cytokines, alone or in any combination, were identified as a candidate biomarker of 
immunotoxic exposure. Within the limitations of the study design, our findings do therefore 
not support the replacement of in vivo studies with in vitro cytokine release for identification 
of immunotoxic substances. In contrast, a transcriptomic profile of 48 genes indicative of 
immunotoxic exposure was found in PBMCs from the same cell cultures (Hochstenbach et 
al., 2010).  
One major challenge with in vitro assays is to distinguish immunotoxic from general 
toxic effects. Initially, viability was determined using the trypan blue exclusion technique to 
select suitable concentrations of the selected substances to be used in the experiments without 
causing general toxic effects. Still, proliferation and the release of most, if not all, nine 
cytokines were strongly inhibited relative to solvent control for some of the concentrations, 
also by the non-immunotoxic substances. PCA based on cytokine release and proliferation 
was therefore used in a further attempt to identify and exclude these possible general toxic 
effects. After exclusion, proliferation was not inhibited by the non-immunotoxic substances, 
indicating that the remaining concentrations did not cause general toxic effects. On the other 
hand, immunotoxic effects may also have been excluded. When effects on cytokine release 
were examined, however, also the non-immunotoxic substances significantly affected 
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cytokine release relative to solvent control for one or more cytokines, possibly reflecting 
general toxic effects. Therefore, in our in vitro system, general toxic effects may still be a 
possible explanation for not being able to distinguish the immunotoxic from the non-
immunotoxic substances. A recently published study reported that inhibition of mitogen-
induced cytokine release from human PBMCs could be used to detect immunotoxic 
substances by comparing the 50% inhibitory concentration (IC50) with the estimated human 
50% lethal concentration (LC50) (Kooijman et al., 2010). If IC50 was lower than LC50, the 
substance was considered to be immunotoxic. With this approach, it may be possible to 
differentiate between general toxic and immunotoxic effects, however, since the approach is 
dependent on availability of human data regarding LC50, it is not suitable for novel 
substances.  
Another limitation of in vitro systems is the difficulty to extrapolate the relevance of 
observed in vitro effects on cells to organs and cells of the immune system and immune 
function in vivo. In the present work, the observed effects on cytokine release after in vitro 
exposure to the non-immunotoxic substances may therefore not be relevant in vivo, which 
may explain that also the non-immunotoxic substances affected the in vitro cytokine release.  
 Although it was not possible to distinguish the immunotoxic from non-immunotoxic 
substances in the present work, observed effects of immunotoxic substances on in vitro 
cytokine release were in agreement with published in vivo and ex vivo animal studies 
(discussed in Paper I). Exposure to TCDD, as an example, was found to suppress the release 
of the cytokines IL-4, IFN- and IL-17 in our in vitro system which is in accordance with the 
ex vivo studies by Ito et al. (2002), Nohara et al. (2002) and Quintana et al. (2008). The 
agreement between studies indicates that in vitro cytokine release may be a useful parameter 
in mechanistic studies of substances causing direct effects on the immune system. This notion 
is in accordance with published literature (Gennari et al., 2005; Lankveld et al., 2010; Levin 
et al., 2008).  
 
6.2 Prenatal exposure to acrylamide and immunotoxicity 
Exposure to acrylamide from the maternal diet during pregnancy was not found to be 
associated with immune-related health outcomes during the three first years of life. 
Furthermore, no associations were found between prenatal exposure to acrylamide and the 
immune-related blood parameters investigated at three years of age. To our knowledge, only 
Zaidi et al. (1994) have reported immunosuppressive properties of acrylamide, but this study 
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was performed in rats. Furthermore, 50 mg/kg bw was administered intraperitoneally (i.p.) 
daily for 10 days (this dose was found to be an optimum dose to induce hind limb paralysis 
within 10 days), resulting in a high dose compared to estimated dietary intake for the general 
human population (1 g/kg bw/day (JECFA, 2005)) and for the present BraMat cohort (0.56 
g/kg bw/day).  
Since the literature about immunotoxic properties of acrylamide in vivo is scarce in 
contrast to literature about carcinogenic, genotoxic, neurotoxic and reproductive toxic 
properties (Carere, 2006; Hogervorst et al., 2010; Parzefall, 2008), acrylamide was defined in 
the in vitro study as a non-immunotoxic substance (Paper I). Shortage of publications, 
however, is not sufficient to conclude that acrylamide does not exert immunotoxic effects, and 
could be a result of a lack of studies and a lack of publication of negative results (publication 
bias). The proposed carcinogenic and neurotoxic properties of acrylamide may suggest that 
acrylamide also has immunotoxic properties since the immune system is both involved in 
killing tumor cells and interacts closely with the nervous system (Murphy et al., 2008; Rosas-
Ballina et al., 2011; Wong et al., 2011). Carcinogenic effects of acrylamide, or its metabolite 
glycidamide, in animal studies have been reported. Furthermore, acrylamide exposure has 
also been reported to be associated with increased risk of cancer in humans (Hogervorst et al., 
2007; Hogervorst et al., 2008; Hogervorst et al., 2010; Wilson et al., 2010). Regarding 
neurotoxicity, it has been reported neurotoxic effects in humans occupationally exposed to 
high levels of acrylamide (Hagmar et al., 2001; Kjuus et al., 2004). To our knowledge, 
neurotoxic effects have not been observed in the general non-smoking population where food 
is assumed to be the major source of acrylamide exposure. Indirect immunotoxic effects due 
to the proposed neurotoxic properties may therefore not be very likely in our study 
population. Although the statistical power may be too low to conclude on negative findings, 
our study is in line with the notion that dietary acrylamide does not exert immunotoxic effects 
in the general non-smoking population. Irrespective of whether acrylamide is an 
immunotoxicant or not, the present nutritional guidelines for pregnant women may ensure low 
exposure since important sources of acrylamide are food items considered to be unhealthy, 
such as potato crisps and deep-fried potatoes (Norwegian food safety authority, 2011a). 
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6.3 Prenatal exposure to PCBs and dioxins and immunotoxicity 
6.3.1 Susceptibility to infections 
Prenatal dietary exposure to PCBs and dioxins was found to be associated with increased 
numbers of upper respiratory tract infections up to three years of age. Furthermore, exposure 
to PCBs and dioxins was associated with an increased risk of the common childhood disease 
exanthema subitum (roseola infantum) during the first year of life, and a tendency of 
increased numbers of gastroenteritis episodes up to three years of age. The results suggest that 
prenatal exposure to PCBs and dioxins is associated with an increased risk of infections, 
indicating immunosuppressive effects (discussed in section 6.3.5), persisting up to the third 
year of life. In agreement with our findings, other studies have reported associations between 
the levels of PCBs and dioxins in blood or breast milk and increased frequency of infections, 
especially lower respiratory tract infections and otitis media (Dallaire et al., 2004; Dallaire et 
al., 2006; Miyashita et al., 2011; Weisglas-Kuperus et al., 2000; Weisglas-Kuperus et al., 
2004). Glynn et al. (2008), however, reported divergent results regarding respiratory 
infections when prenatal exposure to individual congeners of PCBs in Swedish children was 
investigated. 
6.3.2 Wheeze 
Prenatal exposure to PCBs and dioxins from the maternal diet was found to be associated with 
an increased risk of wheeze during the first year and cumulatively during the three first years 
of life. No associations were found, however, between prenatal exposure to PCBs and dioxins 
and wheeze in the third year only. Wheeze may be divided into different phenotypes, and the 
most common are transient infantile wheeze, viral-associated wheeze and atopic wheeze (Sly 
et al., 2008; Stein and Martinez, 2004). However, the division into three phenotypes does not 
mean that the groups are exclusive. Viral-associated wheeze is thought to occur due to 
changes in the airways associated with viral infections. Atopic wheeze is associated with 
sensitisation to aeroallergens and with other atopic diseases, whereas transient infantile 
wheeze is associated with reduced lung function before any event of lower respiratory illness 
has occurred. Any insult that decreases airway diameter or alters airway wall compliance 
could lead to wheeze. In the present work, we were not able to distinguish between the 
wheeze phenotypes (discussed in Papers II and III). When wheeze was combined with the 
number of upper respiratory tract infections (< 7 or  7 episodes of infections) during the first 
year of life, however, we found a significantly stronger association between prenatal exposure 
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to PCBs and dioxins and wheeze along with seven or more episodes of infection compared to 
wheeze along with less than seven episodes (results not shown). Although the statistical 
power of the analysis is low, our results may suggest that the observed association between 
prenatal dietary exposure to PCBs and dioxins and wheeze may be mainly due to respiratory 
infections. The influence of respiratory infections in inducing wheeze may be of less 
importance in later childhood since the diameter of the airways increases as the child grows 
older. The observed decreasing tendency with time of wheeze associated with exposure to 
PCBs and dioxins may therefore further support the notion that the exposure is associated 
with wheeze mainly induced by respiratory infections.  
Weisglas-Kuperus et al. (2000) reported dioxin exposure, as measured in breast milk, 
to be associated with a higher occurrence of coughing, chest congestion and phlegm lasting 
for at least 10 days in 3-4-year-old children. At both 3-4 years of age and at school age, 
however, they reported that prenatal PCB exposure was associated with less shortness of 
breath with wheeze (Weisglas-Kuperus et al., 2000; Weisglas-Kuperus et al., 2004). It is 
difficult to compare our findings and the findings of the two studies of Weisglas-Kuperus et 
al. (2000 and 2004) due to differently formulated questions in the questionnaires. The 
association between exposure and a higher occurrence of coughing, chest congestion and 
phlegm lasting for at least 10 days, however, may reflect respiratory infections, which is in 
concordance with the present work. The associations between exposure and less shortness of 
breath with wheeze at 3-4 years of age and at school age may indicate that the effects of 
prenatal PCB exposure on wheeze may change as the child grows older and the influence of 
respiratory infections in inducing wheeze may become less important. 
6.3.3 Blood parameters 
Antibody responses to five different vaccines included in the Norwegian Childhood 
Vaccination Program were analysed in three-year-old children. Prenatal exposure to PCBs 
and dioxins was found to be associated with a reduced antibody response to the measles 
vaccine. Reduced vaccination responses may be a result of immunosuppression (discussed in 
section 6.3.5) and may indicate a decreased host capacity for immune responses against 
pathogens, which is in accordance with the observed increased number of infections. 
Associations between PCB exposure and reduced antibody responses to vaccines have also 
been reported in other human studies (Heilmann et al., 2006; Heilmann et al., 2010; 
Weisglas-Kuperus et al., 2000). No significant associations were found for antibody 
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responses to vaccines tested other than measles. Effects of exposure to PCBs and dioxins may 
differ for different vaccines as discussed in section 5.3.  
No associations were found between prenatal exposure to PCBs and dioxins and 
immunophenotype data, including regulatory T cell data. Similarly, no associations were 
found between prenatal exposure and allergic sensitization in the three-year-old children. In 
contrast, associations between prenatal exposure to PCBs and dioxins and the levels of 
different leukocyte populations in blood have been reported in other human studies (Glynn et 
al., 2008; Weisglas-Kuperus et al., 1995; Weisglas-Kuperus et al., 2000). One might expect 
to find effects on immunophenotype data since effects on other immune-related endpoints 
were observed. Since immunophenotyping was only performed on about 80 samples in the 
present work, low statistical power may be a reason for the lack of associations. 
Immunophenotyping was also performed on cord blood in the BraMat cohort and another 
Norwegian NewGeneris cohort (n=295). Despite a larger sample size of cord blood 
(compared to blood samples at three years), no associations were found between exposure to 
PCBs and dioxins and the levels of different leukocyte populations in blood (results not 
shown). Our results indicate that functional endpoints such as vaccine antibody responses may 
be more sensitive in identifying associations with toxicant exposures than non-functional 
endpoints as immunophenotype distribution (see discussion in section 5.3).  
6.3.4 Foetal stage, a critical time window? 
As discussed in Paper III, only 5 of the participating mothers had a slightly higher intake than 
the tolerable weekly intake (TWI) of 14 pg TEQ/kg bw/week (set by the EU Scientific 
Committee on Food (Scientific Committee on Food, 2001)). Considering the relative low 
exposure levels, assumed to be representative for the general population (Kvalem, 2010), it 
gives reason for concern that prenatal exposure to PCBs and dioxins was found to be 
associated with changes in immune-related endpoints, even as late as at three years of age. 
The result may be in line with the notion that the foetal stage is a critical time window of 
immune system vulnerability to immunotoxicant exposures (Dietert, 2008; Holsapple et al., 
2004; van Loveren and Piersma, 2004; West, 2002). It is challenging in a cohort study like 
ours, however, to differentiate between prenatal and postnatal dietary exposure of the child. 
Breast-fed children may be exposed to PCBs and dioxins postnatally since these toxicants are 
transferred to breast milk (Ayotte et al., 2003; Polder et al., 2008; Tsukimori et al., 2011), and 
the mother’s diet is probably similar to the diet during pregnancy. Breast-feeding of the 
children was therefore adjusted for in the multivariate analyses. In addition, the children in the 
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present work have also been exposed through their own diet, other than breast milk, to these 
toxicants. Since postnatal exposure data on PCBs and dioxins were not available for the 
BraMat cohort, it was not possible to identify the role of postnatal exposure. However, in a 
subgroup of the BraMat children (n=111), changes in expression of immune-related genes in 
cord blood were found to correlate with both prenatal exposure to PCBs and TCDD and the 
antibody response to the measles vaccine at three years of age (Hochstenbach et al., in 
preparation). This may suggests that the immunosuppression observed in the present work, at 
least in part, was caused by prenatal exposure to PCBs and dioxins.  
Prenatal exposure may result in different types of effects on the immune system 
compared to exposure later in life. An illustrating example is exposure to TCDD and the onset 
of autoimmune diseases in mice. Perinatal exposure in mice is reported to possibly increase 
the risk of developing autoimmune diseases, in contrast to exposure in later life which may 
lower the risk of developing autoimmune diseases (Gogal, Jr. and Holladay, 2008; Holladay 
et al., 2011; Kerkvliet et al., 2009; Li and McMurray, 2009; Quintana et al., 2008; Zhang et 
al., 2010). Humans are exposed to PCBs and dioxins throughout life, and it is therefore 
challenging to distinguish the effects of early life exposure from the effects of exposure in 
later life. 
6.3.5 Mechanisms 
As discussed in Papers II and III, our findings that prenatal PCB and dioxin exposure is 
associated with an increased risk of wheeze and infections, and with reduced levels of 
vaccine-induced antibodies are in accordance with the proposed immunosuppressive 
properties of dioxins and dl-PCBs. Immunosuppression in general is expected to result in 
more infections and less inflammatory diseases such as allergy and autoimmunity. Based on 
animal studies, a proposed mechanistic explanation is that dioxins and dl-PCBs bind to the 
aryl hydrocarbon receptor (AhR) which results in expansion of the population of regulatory T 
cells and subsequently suppressed immune responses (Funatake et al., 2005; Ho and 
Steinman, 2008; Kerkvliet et al., 2009; Marshall et al., 2008; Marshall and Kerkvliet, 2010; 
Quintana et al., 2008). No associations were found in our study between prenatal exposure to 
PCBs and dioxins and relative number of regulatory T cells in blood. The function and 
number of regulatory T cells in tissues with an ongoing inflammatory response, however, may 
not be reflected in blood (Seddiki and Kelleher, 2008), which may explain the lack of 
association between exposure and relative number of regulatory T cells in the present work. 
Furthermore, low statistical power can also be a reason.  
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It is interesting that different high affinity ligands of AhR, such as TCDD (a dioxin) 
and FICZ (a natural photoproduct), may exert divergent effects on the immune system 
(Quintana et al., 2008). In contrast to TCDD, FICZ have been reported to expand the 
population of Th17 cells resulting in increased inflammatory responses. It has earlier been 
proposed that the different effects of TCDD compared to FICZ are due to high toxicity of 
TCDD (Veldhoen et al., 2008). A proportional shift in regulatory T cells may be due to the 
death of other cells rather than an actual expansion in numbers. However, given a major 
difference in half-lives of these ligands in vivo, it is likely that the effects of the prolonged 
exposure to TCDD compared to FICZ can explain the apparent functional differences 
(Stockinger et al., 2011). 
 In the present work, a tendency of lowered risk of eczema or itching with increasing 
prenatal exposure to PCBs and dioxins was found during the first year of life, but no 
significant associations were found for either eczema/itching or doctor diagnosed atopic 
eczema in later childhood. On the other hand, a tendency of increased risk of doctor 
diagnosed allergy was found during the three first years of life, but no significant association 
was found between prenatal exposure to PCBs and dioxins and allergic sensitization at three 
years of age. With regard to allergic diseases in humans, exposure to PCBs and dioxins in 
general has been found to be associated with a reduced risk of allergy and atopic eczema, 
which is confirmed in animal studies (Grandjean et al., 2010; Luebke et al., 2001; Schulz et 
al., 2011; Tarkowski et al., 2010; ten Tusscher et al., 2003; Weisglas-Kuperus et al., 2000). 
However, exposure to PCBs and dioxins has also been found to be associated with increased 
levels of total IgE and a possible increased risk of food allergy (Grandjean et al., 2010; 
Miyashita et al., 2011). Furthermore, it has been reported that TCDD exposure in mice may 
impair the oral tolerance induction, which results in increased risk of sensitization to food 
allergens (Chmill et al., 2010; Kinoshita et al., 2006). Increased levels of total IgE antibodies 
and increased risk of food allergy may suggest that perinatal exposure to PCBs and dioxins 
also affects the Th1/Th2-balance upon birth which may result in Th2 skewness in the foetus 
and early childhood, persisting into later child- and adulthood. Th2 skewness may also be an 
explanation for immunosuppressive effects such as increased susceptibility to infections 
(Luster et al., 2005). Conflicting results regarding allergy in humans may also be due to 
exposure to ndl-PCBs, which may be highly correlated to dioxins and dl-PCBs, but may exert 
effects independent of AhR (Ferrante et al., 2011; Fischer et al., 1998; Levin et al., 2005; 
Lyche et al., 2004; Lyche et al., 2006). 
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6.3.6 Confounding exposure factors 
In the present work, dioxins and dl-PCBs, and ndl-PCBs were found to be highly correlated 
(b= 0.81, p<0.001). Separate statistical analyses were therefore performed and conclusions 
drawn without differentiating between the two groups of PCBs and dioxins. As discussed 
above, our findings on immune-related parameters and prenatal PCB and dioxin exposure are 
in accordance with the proposed immunosuppressive properties of dioxins and dl-PCBs. We 
cannot exclude, however, the possibility that ndl-PCBs may exert similar immunotoxic effects 
independent of AhR. In risk assessments for humans, it may be more important to examine 
the effects of the mixture of PCBs and dioxins than investigating effects of different PCB and 
dioxin congeners individually. The majority of individual PCBs and dioxins possess their own 
intrinsic toxicities, and they can interact additively, synergistically and/or antagonistically, 
resulting in high variation in the effects of mixtures (White and Birnbaum, 2009).  
An important limitation, which is generally valid for all epidemiological studies, is the 
uncertainty about whether other substances or factors contribute to the associations found. n-3 
fatty acids are suggested to have anti-inflammatory properties (Chapkin et al., 2009; Klemens 
et al., 2011; Wall et al., 2010). The calculated maternal intake from food items of the n-3 
long-chain fatty acids eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA) and 
docosahexaenoic acid (DHA) (described in Haugen et al. (2008)) was found to be highly 
correlated with the maternal intake of dioxins and dl-PCBs, and ndl-PCBs (	 = 0.78, p<0.001, 
and 	 =0.80, p<0.001, respectively) as expected due to their common dietary source (seafood) 
and the lipophilic properties of the compounds. Therefore, n-3 fatty acids may possibly 
influence the associations found between exposure to PCBs and dioxins and immune-related 
endpoints in the present work. Due to the high correlation, we could not adjust for these n-3 
fatty acids in the statistical analyses. However, when investigating prenatal exposure to the 
long chain n-3 fatty acids from food items and health outcomes (0-3 and 2-3 years of age), a 
significant association was only found for wheeze during the three first years of life (bivariate 
analysis; OR (95% CI) p-value; 2.37 (1.03-5.46) 0.043). Interestingly, no associations were 
found between long chain n-3 fatty acids from dietary supplements and health outcomes 
(results not shown). Since dietary supplements containing n-3 fatty acids are purified to 
remove toxicants such as PCBs and dioxins, these results may suggest that exposure to PCBs 
and dioxins, rather than n-3 fatty acids, is most important for the immunosuppression found in 
the present work.   
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6.3.7 Implications of the findings 
The findings in the present work may suggest that prenatal exposure to levels of PCBs and 
dioxins from the maternal diet representative for the general population increases the risk of 
wheeze and infections during the three first years of life. Reducing the level of dietary 
exposure to these toxicants for women of fertile age may therefore be beneficial for their 
children’s health. For the pregnant women in the BraMat cohort, fat fish was an important 
source of exposure to PCBs and dioxins. Since fish also provides a healthful source of dietary 
proteins and is high in nutrients that may have beneficial effects on human health, such as n-3 
fatty acids (Costa, 2007), reducing or avoiding fish in the diet, in general, is not advised by 
the Norwegian authorities (Norwegian food safety authority, 2011b). However, for women of 
fertile age it is recommended to reduce or avoid consumption of food items with possible high 
levels of PCBs and dioxins such as the most polluted fish, brown meat of crabs and food 
items containing fish liver (Norwegian food safety authority, 2011a; Norwegian food safety 
authority, 2011c). Furthermore, it is recommended to avoid consumption of seagull eggs, 
which may be highly contaminated with PCBs and dioxins. Consumption of seagull eggs was 
reported by 5 of the mothers in the BraMat cohort. The results of the present work are in line 
with the dietary advice from the authorities to women of fertile age. 
 
6.4 Future perspectives 
In the in vitro study, it was not possible to distinguish immunotoxic from non-immunotoxic 
substances by investigating effects on in vitro cytokine release. However, a transcriptomic 
profile indicative of immunotoxic exposure was identified in PBMCs from the same cell 
cultures (Hochstenbach et al., 2010). Considering today’s search for alternative methods to 
the use of animals in toxicity testing of chemicals (Balls et al., 1995), it is important to 
continue working on developing reliable in vitro methods able to predict immunotoxicity, 
such as methods based on the promising tool transcriptomics. 
The number of participants in the BraMat birth cohort was found to be sufficient to 
find associations between toxicant exposure and health outcomes and blood parameters. Still, 
studies should preferentially be performed in a cohort with more participants to increase the 
statistical power, especially regarding acrylamide, to be able to conclude on the negative 
findings. More statistical power may also be needed to further investigate the associations and 
the tendencies of associations found for PCBs and dioxins to sufficiently adjust for all 
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possible confounders in the final multivariate model to obtain more precise effect estimates 
and narrower CI. Furthermore, additional associations may be found in a larger study 
population, and it may be possible to identify vulnerable subgroups.  
Dietary exposure to PCBs and dioxins during pregnancy was investigated in the 
present work, whereas exposure data later in childhood were not available. If possible, also 
postnatal dietary exposure to the toxicants should be determined to investigate whether the 
prenatal, postnatal or both periods are critical time windows of exposure. In addition, it would 
be of interest to compare the relative importance of maternal blood levels (body burden) and 
the dietary intake during pregnancy of these toxicants and their immune-related effects in the 
child. 
Regarding acrylamide, it is of interest to study whether immunotoxic effects in 
occupationally exposed humans occur, since neurotoxic effects in these highly exposed 
humans have been reported. Occupational exposure may not be comparable to prenatal dietary 
exposure since the exposure routes are different, the foetus may be more sensitive to toxicant 
exposure than adults, and different effects may appear. However, if no immunotoxicity is 
observed in occupationally exposed humans, it may suggest that prenatal exposure to 
acrylamide from food does not exert immunotoxic effects in the general population. 
Furthermore, more animal studies may be valuable to gain knowledge about whether prenatal 
dietary exposure to acrylamide exerts immunotoxic effects. 
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7 Conclusions 
 
Based upon the results from the present work and the literature, as discussed in the present 
thesis, the following conclusions may be drawn: 
 
• The effect of the 12 selected substances on in vitro cytokine release from PBMCs did 
not reflect the in vivo-based classification of their immunotoxic potential according to 
published data. Within the limitations of the study design, our results therefore do not 
support the replacement of in vivo studies with in vitro cytokine release for 
identification of immunotoxic substances. 
 
• Prenatal exposure to acrylamide from the maternal diet was not found to be associated 
with immune-related health outcomes or blood parameters during the three first years of 
life, but the statistical power may be too low to conclude on negative findings. Prenatal 
exposure to PCBs and dioxins from the maternal diet was found to be associated with an 
increased risk of wheeze up to three years of age (0-1 and 0-3 years), but not during the 
third year of life (2-3 years). The data suggest that the wheeze mainly was  
infection-induced. Furthermore, prenatal exposure to PCBs and dioxins was found to be 
associated with increased frequency of infections during the three first years of life. 
Prenatal exposure to PCBs and dioxins was also associated with reduced levels of 
vaccine-induced antibodies to measles at three years of age. Overall, the results suggest 
that prenatal exposure to PCBs and dioxins may result in immunosuppression and 
thereby increased susceptibility to infections in early childhood. A continued effort to 
reduce the exposure to PCBs and dioxins from food for women of fertile age appears 
therefore to be beneficial for their children’s health. 
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Abstract 
We investigated whether prenatal exposure from the maternal diet to the toxicants acrylamide, 
polychlorinated biphenyls (PCBs) and dioxins affected the development of immune-related 
diseases in childhood. Children participating in BraMat, a sub-cohort of the Norwegian 
Mother and Child Cohort Study (MoBa), were followed in the three first years of life using 
annual questionnaires (0-3 years; n = 162, 2-3 years; n = 180), and blood parameters were 
examined at three years of age (n = 114). The maternal intake of the toxicants was calculated 
using a validated food frequency questionnaire from MoBa. Prenatal dietary exposure to 
PCBs and dioxins was found to be associated with an increased risk of wheeze (defined as 
periods of more than 10 days of dry cough, chest tightness, or wheeze) and more frequent 
upper respiratory tract infections during the three first years of life. Furthermore, at three 
years of age, prenatal exposure to PCBs and dioxins was associated with reduced antibody 
response to the measles vaccine. No associations were found between prenatal exposure and 
immunophenotype data including regulatory T cells, allergic sensitization, and vaccine 
antibody responses other than measles. Prenatal acrylamide exposure was neither found to be 
associated with health outcomes nor blood parameters. Our results suggest that prenatal 
dietary exposure to PCBs and dioxins may increase the risk of wheeze and the susceptibility 
to infectious diseases during early childhood. 
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1. Introduction 
Food items may contain environmental toxicants like the organochlorines polychlorinated 
biphenyls (PCBs) and polychlorinated dibenzo-p-dioxins/dibenzofurans (PCDDs/PCDFs, 
commonly called dioxins), as well as toxicants generated during food preparation like 
acrylamide. PCBs and dioxins are highly lipophilic and accumulate in the food chain. The diet 
is assumed to be the main source of human exposure to these substances, providing more than 
90% of the total exposure (Domingo and Bocio, 2007). The diet is also assumed to be the 
main source of exposure to acrylamide for the general non-smoking population. Acrylamide is 
formed during heat treatment at temperatures above 120 °C, particularly in plant-derived 
foods rich in carbohydrates (Mottram et al., 2002; Stadler et al., 2002). 
Studies have shown that acrylamide, PCBs and dioxins cross the placenta and reach 
the foetus (Annola et al., 2008; Covaci et al., 2002; Suzuki et al., 2005). Prenatal exposure to 
immunotoxicants is of concern since the foetus may be especially vulnerable due to an 
extensively developing immune system (Holsapple et al., 2004; van Loveren and Piersma, 
2004). Adverse effects on the immune system may result in immune-related diseases like 
allergy, asthma, and autoimmune conditions, or increased susceptibility to infectious diseases.  
We have previously examined in the birth cohort BraMat whether exposure to 
acrylamide, PCBs and dioxins from the maternal diet during pregnancy exert immunotoxic 
effects in the children’s first year of life. No associations between prenatal dietary exposure to 
acrylamide and immune-related health outcomes were found. In other studies, it has been 
reported on carcinogenic, genotoxic, neurotoxic, and reproductive toxic properties of 
acrylamide (reviewed by Hogervorst et al. (2010) and Parzefall (2008)). Information on 
immunotoxicity of acrylamide is scarce. The carcinogenic and neurotoxic properties of 
acrylamide may indicate that acrylamide also has immunotoxic properties since the immune 
system is involved in killing harmful tumor cells, and the nervous system may influence the 
immune system (Murphy et al., 2008). 
The results in our previous study suggested that prenatal dietary exposure is associated 
with an increased risk of wheeze and infections during the first year of life (Stolevik et al., 
2011). In agreement with these findings, health effects of prenatal exposure to PCBs and 
dioxins in humans have been reported by others such as increased frequency of infections, 
less atopic dermatitis, and reduced antibody responses to vaccines (Dallaire et al., 2004; 
Dallaire et al., 2006; Glynn et al., 2008; Grandjean et al., 2010; Heilmann et al., 2006; ten 
Tusscher et al., 2003; Weisglas-Kuperus et al., 2000; Weisglas-Kuperus et al., 2004). These 
studies have measured the concentrations of the toxicants in biological media such as cord 
blood and breast milk, indicating the body burden of the toxicants. In contrast, we 
investigated the effect of exposure through the diet using an extensive and well validated food 
frequency questionnaire (FFQ) (Brantsaeter et al., 2008a; Meltzer et al., 2008). An advantage 
of using FFQ data are that the results may indicate how exposure to toxicants from the diet 
affects the health of the children, which is valuable information to be used in counselling 
women in fertile age regarding their diet. 
The present study is part of the EU-funded project NewGeneris with the main aim to 
investigate whether maternal exposure to dietary toxicants results in in utero exposure and 
molecular events in the unborn child, leading to an increased risk of cancer and immune 
disorders in childhood (Merlo et al., 2009). The present paper reports the results from the 
three-year follow-up of the children participating in the birth cohort BraMat. To investigate 
immunotoxic effects of PCBs and dioxins, as well as acrylamide, questionnaire data, 
concentrations of allergen specific IgE antibodies, vaccine antibody titers, and 
immunophenotype data including regulatory T cells, were examined. 
2. Materials and methods 
 
2.1. Study population 
The BraMat cohort (n=205) was established between April 2007 and March 2008. Invitations 
to participate in the birth cohort BraMat were sent by regular mail to all pregnant women 
already enrolled in the Norwegian Mother and Child Cohort Study (MoBa) and who were 
scheduled to give birth at Oslo University Hospital Ullevål or Akershus University Hospital 
(recruitment rate ~25%). MoBa is a prospective population-based pregnancy cohort study 
conducted by the Norwegian Institute of Public Health, including 108.000 children from all 
over the country born between 1999-2008 (Magnus et al., 2006). Invitations to the BraMat 
birth cohort was sent in week 37 of gestation, thus only infants who had experienced a full 
term pregnancy (37th - 42nd week of gestation) were included. There were no plurality births. 
Exclusion criteria for the BraMat cohort were autoimmune diseases of the mother and use of 
steroids, anti-inflammatory, or epileptic drugs during pregnancy. The study was approved by 
the Norwegian Regional Committee for Medical and Health Research Ethics and the Data 
Inspectorate. All mothers gave their written informed consent both to MoBa and BraMat. 
 
2.2. Blood sampling and handling 
Venous blood was collected from the three year old children (age mean (range), 36 (33-43) 
months) either at their doctor’s office, at home by a technician, or at a commercial laboratory 
(Fürst medical laboratory). Blood was collected into BD Vacutainer®SST™II serum gel 
separation tubes with butterfly blood collection sets (BD, Franklin Lakes, NJ, USA). The 
blood was allowed to clot for at least 30 min before centrifugation at 1000-1300g for 10 min 
at room temperature. Aliquots of the serum samples were stored at -20 °C until further 
analyses. Blood was also collected into EDTA BD Vacutainers® (BD) and kept at room 
temperature until analyses were performed.  
 
2.3. Determination of vaccine responses 
As a measure of the immune function of the children, antibody responses to five of the 
vaccines in the Norwegian Childhood Vaccination Program were examined.  
 
2.3.1 Viral vaccine antibody titers  
The serum samples were analyzed for anti-measles IgG antibodies using Enzygnost Anti-
Measles Virus IgG ELISA (Siemens, Marburg, Germany) and for anti-rubella IgG antibodies 
using Serion Rubella Virus IgG ELISA (Virion/Serion, Würzburg, Germany). Both assays 
were performed as recommended by the manufacturers. With the measles assay, the cut-off 
for qualitative evaluation of positivity was an optical density (OD) of 0.2 at 450 nm, 
corresponding to approximately 400 U/ml, as recommended by the manufacturer. With the 
rubella assay, the cut-off values to identify rubella positivity were calculated separately for 
each run, according to manufacturer’s instructions.  
 
2.3.2 Bacterial vaccine antibody titers 
Concentrations of specific IgG antibodies to tetanus toxoid (Simonsen et al., 1986), 
pneumococcal polysaccharides (Aaberge et al., 1996), and Haemophilus influenzae type b 
(Hib) (modified from (Phipps et al., 1990)) were determined using ELISA techniques. The 
antibody concentration to tetanus toxoid was given as IU/ml. IgG antibodies to a mix of 23 
serotypes of pneumococcal polysaccharides (PPV23, Pneumovax®, Sanofi Pasteur MSD) 
were measured after C polysaccharide (CPS) adsorption of the sera (Statens Serum Institut, 
Copenhagen, Denmark). The IgG antibody concentration to PPV23 was given as arbitrary 
units (AU/ml). Regarding the anti-Hib assay, microtiter plates were coated with Hib 
oligosaccharide conjugated to human albumin (1 mg/ml) (NIBSC, Potters Bar, UK). The 
serum samples were diluted two-fold starting at dilution 1:10. Goat anti-human IgG-alkaline 
phosphatase (ALP) (Sigma-Aldrich, St. Louis, MO, USA) was used as conjugate. The 
concentration of specific antibodies was calculated using human anti-Hib capsular 
polysaccharide serum as standard (LOT no. 1983; FDA, Silver Spring, MD, USA).   
 
2.4. Determination of allergen specific IgE 
The serum samples were analysed for allergen-specific IgE antibodies using ImmunoCAP 
Phadiatop® Infant (Phadia AB, Uppsala, Sweden) containing 11 allergens selected to be 
relevant for young children (house dust mite, cat, dog, hen’s egg, cow’s milk, peanut, shrimp, 
timothy, birch, ragweed, and Parietaria judaica). The concentrations of antibodies were 
expressed as Phadia Arbitrary Units/l (PAU/l) indicating the degree of sensitisation. Children 
with antibody concentrations  0.35 PAUಞ/l were considered to be sensitized.  
Sera from the children found to be sensitized using Phadiatop Infant, were analysed 
for specific IgE antibodies to the single allergens from house dust mite, cat, dog, hen’s egg, 
cow’s milk, peanut, timothy, and birch. The concentrations of antibodies were expressed as 
kU/l, and children with antibody concentrations  0.35 kU/l were considered to be sensitized. 
The analyses were performed as recommended by the manufacturer. 
 
2.5. Immunophenotyping by flow cytometry 
Within 24h, immunophenotyping was performed on whole blood samples according to the 
protocol of the manufacturer (BD). In short, the blood samples were stained with the 
antibodies in the Multitest 6-color TBNK reagent (FITC-labelled anti-CD3, PE-labelled anti-
CD16 and anti-CD56, PerCP-Cy5.5-labelled anti-CD45, PE-Cy7-labelled anti-CD4, APC-
labelled anti-CD19, APC-Cy7-labelled anti-CD8; BD) and Pacific Blue-labelled anti-CD14 
(BD) for 15 min in the dark at room temperature. Red blood cells were lysed in FACS lysing 
solution (BD) by incubation for 15 min in the dark at room temperature. The cells were 
counted using a BD LSRII flow cytometer with BD FACSDiva Software version 6.1.2. The 
lymphocytes were gated based on side light scatter (SSC) and CD45 expression, and 
monocytes were gated based on CD14 and CD45 expression. The percent and absolute 
numbers of the following lymphocyte subsets were determined: T-lymphocytes (CD3+), T-
helper cells (CD3+CD4+), cytotoxic T-lymphocytes (CD3+CD8+), B-lymphocytes (CD19+), 
natural killer (NK) cells (CD16+CD56+), and natural killer T-lymphocytes 
(CD3+CD16+CD56+). Absolute numbers of the leukocytes (cells/l) were determined by the 
use of Truecount tubes (BD). 
For assessment of regulatory T cells, the blood samples were stained with the 
antibodies in the Human Regulatory T cell Coctail (FITC-labelled anti-CD4, PE-Cy7-labelled 
anti-CD25, Alexa647-labelled anti-CD127; BD) for 30 min in the dark at room temperature. 
After lysing of red blood cells, the cells were washed twice and centrifuged at 200g for 5 min 
at 18 °C, and resuspended in 400 l washing buffer. The percent of regulatory T cells was 
determined using a four steps gating strategy. The lymphocytes were gated based on their 
light scatter properties (side scatter (SSC)/forward scatter (FSC)), and duplicates of 
lymphocytes were excluded by gating based on FSC-width and FSC-area. CD4+ cells were 
then further gated based on SSC and CD4 expression. Finally, regulatory T cells were 
determined as percent CD127 low CD25 high cells of CD4+ cells. 
 
2.7. Assessment of exposure to the dietary toxicants 
Maternal intake of the dietary toxicants PCBs, dioxins, and acrylamide, was calculated from a 
validated food frequency questionnaire (FFQ) used in MoBa. Description and validation of 
the FFQ is given elsewhere (Brantsaeter et al.,  2008a; Meltzer et al.,  2008). The FFQ covers 
the dietary intake of the mothers during the first four months of pregnancy. The method for 
estimation of exposure to PCBs, dioxins, and acrylamide has been described in Kvalem et al. 
(2009) and Brantsaeter et al. (2008), respectively. PCBs and dioxins can be divided into two 
groups according to their toxicological properties: 1) dioxins and dioxin-like PCBs (dl-PCBs) 
and 2) non-dioxin-like PCBs (ndl-PCBs). Similar toxicological properties of dioxins and dl-
PCBs allow the combined exposure to be expressed as toxic equivalents (TEQ) (van den Berg 
et al., 2006). The exposure was expressed relative to the mother’s self-reported body weight 
(bw) before pregnancy, thus the exposure to dioxins and dl-PCBs was expressed as pg 
TEQ/kg bw/day, exposure to ndl-PCBs as ng/kg bw/day, and acrylamide as g/kg bw/day.  
 
2.8. Health outcomes from questionnaires 
When the children in the BraMat cohort were one, two, and three years of age, a questionnaire 
was sent to the mothers. The mothers had the choice of filling in the questionnaire and 
returning it by regular mail, or to give the answers by a telephone interview. The 
questionnaire covered topics related to the child’s infectious diseases, allergy, asthma, and 
other chronic diseases, and the use of medications. Concerning infectious diseases, the 
mothers were asked if the child had experienced the following diseases/complaints, and how 
many episodes: colds and other upper respiratory tract infections, otitis media, pneumonia, 
gastroenteritis with vomiting or diarrhoea, and urinary tract infection. The mothers were also 
asked if the child had experienced any children’s diseases, such as chicken pox and 
exanthema subitum (roseola infantum). Concerning allergy, asthma, and other chronic 
diseases, the mothers were asked: “Has the child been diagnosed with asthma, asthma 
bronchitis, or bronchial hyperreactivity by a doctor? Has the child had periods of more than 
10 days of dry cough, chest tightness, or wheeze (hereafter called wheeze)? Has the child had 
eczema or itchiness (in the face or at joints such as the groin, popliteal fossa, ankle, elbow, 
and wrist)? Has the child been diagnosed with atopic dermatitis by a doctor? Has the child 
been diagnosed with allergy by a doctor? Has the child any other chronic disease?” 
Cumulative data (0-3 years of age) and data for the last year only (2-3 years of age) were 
investigated. 
 
2.9. Potential confounding variables 
Potential confounding variables were extracted from the BraMat questionnaires and MoBa 
questionnaires filled in by the mothers during pregnancy (~15th and 30th week of gestation) 
and ~ 6 months after birth (version 5 of the quality-controlled MoBa data files). Birth-related 
information was extracted from the Medical Birth Registry of Norway (MBRN). Potential 
confounding variables included in the analyses were mother’s previous breast-feeding, parity, 
maternal and paternal asthma and allergy, maternal age, maternal smoking, maternal passive 
smoking, maternal education, maternal BMI before pregnancy, mean parental gross income 
for the three years of the study, child’s gender, season of birth, type of delivery, apgar score, 
gestational age, birth weight, number of older siblings, breast-feeding of the child, and day-
care attendance. The categories of the variables used in the analyses are shown in  
Table 1. 
 
2.10. Statistical analyses 
If p<0.1 in bivariate analyses, multivariate logistic regression analyses were applied to assess 
the influence of exposure on the different binary health outcomes for the children. The 
exposure levels of the dietary toxicants were categorised using the 80th percentile to compare 
the highest exposed participants constituting the upper tail of the exposure distribution, with 
the remaining participants (80th percentile and <80th percentile respectively). If no 
statistically significant associations were found, also the continuous exposure variables were 
examined. The criterion for inclusion of potential confounding variables in the multivariate 
regression analyses was p<0.25 in bivariate analyses. Highly correlated variables (correlation 
coefficients  0.7) were not included in the same multivariate analysis. Since the exposure 
levels of dioxins and dl-PCBs, and ndl-PCBs were highly correlated, separate multivariate 
analyses were performed for the two groups of dietary toxicants. Parity, previous breast-
feeding, and number of older siblings were also highly correlated, therefore only parity was 
included in the multivariate analyses. The manual backward deletion method was used 
starting with all included variables in the model. At each deletion step, the least significant 
potential confounding variable in the multivariate model was manually removed until only 
statistically significant (p<0.05) variables remained in the model. Hosmer-Lemeshow test, 
Cooks’D, and residuals were used to investigate the robustness of the results.  
The outcome variables “numbers of upper respiratory tract infections (URTI)” and 
“numbers of gastroenteritis” consist of count data, but linear regression analyses were applied 
since the residuals were approximately normally distributed. Since the numbers of URTI were 
ln-transformed, the reported results for the numbers of URTI are back-transformed values 
(ratios). The multivariate analyses were performed as described above. Cooks’D, Leverage 
values and residuals were used to investigate the robustness of the results.  
Linear and logistic regression analyses were performed on immunophenotype data, 
vaccine antibody titers, and concentrations of allergen specific IgE antibodies. Due to small 
sample size, ln-transformed exposure variables were used to avoid results to be strongly 
influenced by only a few observations. The outcome variable was ln-transformed when 
necessary to fulfil the criteria of normally distributed residuals. For the transformed outcome 
variables, back-transformed values are reported (ratios). Multivariate regression analyses were 
performed as described above. Regarding vaccine responses, children reported not to follow 
the Norwegian Childhood Vaccination Program (n=2) were excluded from the statistical 
analyses. 
Results were considered statistically significant at p<0.05. The statistical analyses 
were performed using the statistical software PASW Statistics 17 (SPSS Inc., Chicago, IL, 
USA).  
3. Results 
 
3.1. Questionnaires and blood samples 
BraMat questionnaires were received from 195 (95%), 184 (90%), and 180 (88%) of the 205 
participants for the first, second, and third year, respectively. All three questionnaires were 
received from 162 (79%) participants. Some of the questionnaires were incomplete. Exposure 
data were given as intake per kg bodyweight. Since the body weight was unknown for five of 
the mothers, exposure data could not be calculated and they were excluded from the statistical 
analyses. Data on health outcomes and potential confounders for some of the children were 
also missing. The total numbers of children included in the different multivariate analyses are 
given in Table 4.  
Blood was collected from 112 (56%) children with exposure data. Due to logistic 
challenges, immunophenotyping and regulatory T cell assessment was only performed for 81 
and 78 samples, respectively. Vaccine antibody titers and concentrations of allergen specific 
IgE antibodies were measured in 110-111 samples. There were no statistically significant 
differences with regard to frequency of health outcomes in children giving and not giving a 
blood sample at three years of age. 
 
3.2. Demographics, frequencies of health outcomes, and exposure levels 
Demographics and the frequencies of the health outcomes for the children included in the 
statistical analyses are shown in Table 1. Few children had experienced pneumonia, urinary 
tract infection, or “other chronic diseases”, therefore statistical analyses were not performed 
for these health outcomes. For the same reason, analyses for the health outcomes “doctor 
diagnosed asthma and allergy, frequency of children’s diseases, and numbers of 
gastroenteritis” were performed on cumulative data (0-3 years) only. The calculated maternal 
dietary intake of dioxins and dl-PCBs, ndl-PCBs, and acrylamide is presented in Table 2. 
 
3.3. Health outcomes 
The results of bivariate logistic or linear regression analyses are presented in Table 3. No 
significant associations between prenatal dietary exposure to acrylamide and the investigated 
health outcomes were found. 
 
3.3.1. Cumulative data (0-3 years of age) 
In multivariate analyses, prenatal exposure to dioxins and dl-PCBs, and ndl-PCBs was 
significantly associated with an increased risk of wheeze (Table 4). In the final multivariate 
model, the OR was adjusted for maternal asthma and allergy and maternal education, and also 
gross income for dioxins and dl-PCBs. Furthermore, prenatal exposure to dioxins and dl-
PCBs, as well as ndl-PCBs was associated with increased numbers of URTI when the 
continuous variables of the toxicants were used. In the final models, the  was adjusted for 
maternal BMI, maternal education, and gestational age, and also birth season for ndl-PCBs. 
Also, prenatal exposure to dioxins and dl-PCBs, and ndl-PCBs was associated with increased 
numbers of gastroenteritis, however, the associations were not robust as indicated by the 
residuals and Cooks’D. The  was adjusted for apgar score in the final models. Finally, 
prenatal exposure to ndl-PCBs was associated with an increased risk of doctor diagnosed 
allergy, but the association was not robust as indicated by residuals and Cooks’D. The OR 
was adjusted for maternal smoking (ever smoked), type of delivery, and day-care attendance 
in the final model. 
 
 
3.3.2. Last year (2-3 years of age) 
In multivariate analyses, prenatal exposure to dioxins and dl-PCBs, and ndl-PCBs was 
associated with increased numbers of URTI (Table 4). However, for ndl-PCBs, a significant 
association was found only when the continuous exposure variable of the dietary toxicants 
was used. The dietary toxicant variables were the only variables remaining in the final 
multivariate models. No significant associations were found for wheeze during the third year 
(Table 3). 
 
3.4. Blood parameters 
No significant associations were found between prenatal exposure to dioxins and dl-PCBs, 
ndl-PCBs, or acrylamide and the levels of different subpopulations of leukocytes in peripheral 
blood (results not shown). Regarding vaccine antibody titers, prenatal exposure to dioxins and 
dl-PCBs, and ndl-PCBs were associated with reduced levels of anti-measles antibodies in 
multivariate analyses (Table 5). The dietary toxicant variables were the only variables 
remaining in the final multivariate models. None of the other vaccine antibody titers were 
significantly associated with exposure to dioxins and dl-PCBs, ndl-PCBs, or acrylamide. 
Twenty three of 111 (20.7 %) children were found to be sensitized using Phadiatop Infant. Of 
these 23 children, 15 were found to be sensitized to at least one food allergen, 9 to at least one 
inhalant allergen, whereas 5 children were not found to be sensitized to any individual 
allergens tested. In bivariate logistic regression analyses, no significant associations were 
found between exposure to the dietary toxicants and sensitization (Table 5).  
 
 
4. Discussion 
In this study, we found that prenatal dietary exposure to PCBs and dioxins was associated 
with an increased risk of wheeze (periods of more than 10 days of dry cough, chest tightness, 
or wheeze) and numbers of upper respiratory tract infections (URTI) during the three first 
years of life, and reduced levels of vaccine-induced anti-measles antibodies at three years of 
age. No associations were found with immunophenotype data or allergic sensitization. 
Furthermore, no associations were observed between prenatal dietary exposure to acrylamide 
and the health outcomes or the blood parameters investigated. 
 The association found between exposure to PCBs and dioxins and an increased risk of 
wheeze during the three first years of life is in accordance with previous reported results from 
this birth cohort (BraMat), where prenatal dietary exposure to PCBs and dioxins was 
associated with an increased risk of wheeze during the first year of life (Stolevik et al.,  2011). 
This association, however, was not found when investigating only the third year. Wheeze may 
be divided into distinct phenotypes (reviewed by Sly et al. (2008)). It was not possible to 
differentiate between wheeze phenotypes in the present study, however, the decreasing 
tendency with time of wheeze associated with exposure to PCBs and dioxins may suggest that 
the exposure was mainly associated with infection-induced wheeze. Since the diameter of the 
airways increases as the child grows older, the influence of infections in inducing wheeze may 
be of less importance in later childhood. Weisglas-Kuperus et al. (2000 and 2004) have also 
reported on wheeze and wheeze-related symptoms, however, it is difficult to compare the 
results in the present study and the two studies of Weisglas-Kuperus et al. (2000 and 2004) 
due to differences in the formulations of questions in the questionnaires. To examine whether 
prenatal dietary exposure to PCBs and dioxins is associated with persistent wheeze or asthma, 
a follow-up into later childhood is needed. 
 In the present study, prenatal dietary exposure to PCBs and dioxins was found to be 
associated with increased numbers of URTI. During the three first years of life, also a 
tendency of increased numbers of gastroenteritis was found. This is in accordance with 
previous findings in this cohort at 1 year of age (Stolevik et al.,  2011) and findings in other 
studies, especially for lower respiratory tract infections and otitis media (Dallaire et al.,  2004; 
Dallaire et al.,  2006; Miyashita et al., 2011; Weisglas-Kuperus et al.,  2000; Weisglas-
Kuperus et al.,  2004). We also found that prenatal exposure to PCBs and dioxins was 
associated with reduced levels of vaccine-induced anti-measles antibodies at three years of 
age which is in agreement with results reported in other studies (Heilmann et al.,  2006; 
Heilmann et al., 2010; Weisglas-Kuperus et al.,  2000). The present findings on reduced 
antibody response to the measles vaccine as well as increased numbers of URTI may indicate 
that prenatal exposure to PCBs and dioxins is associated with immunosuppression that may 
result in increased susceptibility to infectious diseases.  
In contrast to other studies, prenatal dietary exposure to PCBs and dioxins was not 
found to be associated with the levels of different subpopulations of leukocytes in peripheral 
blood in the present study (Glynn et al.,  2008; Weisglas-Kuperus et al.,  2000). Since 
immunophenotyping in the present study was only performed on 78-80 samples, low power 
may be a reason for the different results. In general, changes in the levels of different 
leukocytes may be expected when effects on frequency and prevalence of diseases are 
observed, but the method may have insufficient sensitivity (reviewed by Luster et al. (2005)). 
Overall, our results indicate that in humans functional immunological endpoints like vaccine 
responses are more sensitive in identifying associations with chemical exposures than non-
functional endpoints like immunophenotype data.  
 The associations found between prenatal dietary exposure to PCBs and dioxins and 
increased risk of wheeze, increased numbers of URTI, and reduced antibody response to a 
vaccine are all in accordance with the proposed immunosuppressive properties of dioxins and 
dl-PCBs. A suggested mechanistic explanation is that dioxins and dl-PCBs bind to the aryl 
hydrocarbon receptor (AhR) with a resulting expansion of the population of regulatory T cells 
with subsequent down-regulation of immune responses (Kerkvliet et al., 2009; Quintana et 
al., 2008).  
No significant associations were found between prenatal dietary exposure to 
acrylamide and immunological health outcomes or blood parameters. The study population 
may be too small, however, to conclude on negative findings. New studies should be 
performed in a cohort with more participants to improve the statistical power.  
It gives rise to concern that prenatal exposure to PCBs and dioxins was found to be 
associated with immune-related endpoints, even for the third year of life, especially since only 
5 of 205 participating mothers had slightly higher intake than the tolerable weekly intake 
(TWI) of 14 pg TEQ/kg bw/week (set by the EU Scientific Committee on Food (Scientific 
Committee on Food, 2001)). This supports the notion that the foetal stage is a critical time 
window for exposure (Dietert, 2008; Holsapple et al.,  2004; van Loveren and Piersma,  
2004). It is difficult, however, to differentiate between prenatal and postnatal exposure from 
the child’s diet. In the present study, the children have been exposed to PCBs and dioxins also 
postnatally from breast milk (Ayotte et al., 2003) and food items. Thus, based on the exposure 
data available for the birth cohort used, it was not possible to identify the existence of a 
critical time window during foetal stage and early childhood for exposure to PCBs and 
dioxins.  
The strengths of our study are that the food frequency questionnaire used is well 
validated (Brantsaeter et al.,  2008a), and that extensive information about the children and 
their mothers is available from MoBa and MBRN. Furthermore, the potential selection bias in 
MoBa has been evaluated, and no differences regarding 8 well-known associations between 
MoBa participants and all women giving birth in Norway was found, suggesting no influential 
selection bias in MoBa (Nilsen et al., 2009). However, selection bias due to the low 
recruitment rate to the BraMat cohort (25% of the invited MoBa participants) cannot be 
excluded. Regarding information bias, we have previously reported that no significant 
differences were found for frequency of health outcomes when comparing written 
questionnaires and telephone interviews for the birth cohort BraMat at 1 year of age (Stolevik 
et al.,  2011).  
Long-chain n-3 fatty acids from fish may influence the associations found in the 
present study due to their suggested anti-inflammatory effects (reviewed by Chapkin et al. 
(2009)). As expected due to their common source sea food and the lipohilic properties of the 
toxicants, the maternal intake during pregnancy from food items of the n-3 long-chain fatty 
acids eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), and docosahexaenoic acid 
(DHA) (calculated as described in (Haugen et al., 2008)) were highly correlated with the 
intake of dioxins and dl-PCBs and ndl-PCBs (	 = 0.8). Therefore, we could not adjust for 
these n-3 fatty acids in the statistical analyses. However, when it comes to health outcomes, a 
significant association was only found between the prenatal exposure to n-3 fatty acids from 
food items and wheeze during the three first years of life (bivariate analysis; OR (95% CI) p-
value; 2.37 (1.03-5.46) 0.043) and no other health outcomes found to be associated with PCB 
and dioxin exposure (results not shown). No associations were found for n-3 fatty acids from 
dietary supplements (purified to remove PCBs and dioxins), which may suggest that exposure 
to PCBs and dioxins, rather than n-3 fatty acids, is most important for the immunosuppression 
found in the present study.   
In conclusion, exposure to acrylamide from the maternal diet during pregnancy was 
not found to be associated with either immune-related health outcomes or with blood 
parameters in children during the three first years of life. Our study suggests that prenatal 
dietary exposure to PCBs and dioxins is associated with immunosuppression that persists into 
early childhood. Overall, a continued effort to reduce the exposure to PCBs and dioxins from 
the diet for women in fertile age may be beneficial for their child’s health.  
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Table 1. Demographics of the BraMat study population included in the statistical analyses on 
cumulative (n = 158) and last year (n = 176) questionnaire data, and blood parameters (n = 112).  
Demographics    
  
Cumulative 
n (%) 
Last year 
n (%) 
Blood parameters 
n (%) 
Eczema/Itchiness (yes)   74 (49.0) 54 (31.4) 36 (33.3) 
Doctor diagnosed atopic eczema (yes) 33 (21.2) 28 (16.0) 18 (16.4) 
Doctor diagnosed allergy (yes)  16 (10.3) 13 (7.4) 8 (7.2) 
Wheeze (yes)    61 (38.6) 34 (19.3) 22 (19.8) 
Use of asthma medicine (yes) 37 (23.4) 32 (18.2) 16 (14.4) 
Doctor diagnosed asthma (yes)  20 (12.7) 16 (9.1) 9 (8.1) 
Upper respiratory tract infections (mean (min-max)) 10 (0-35) 3 (0-20) 3 (0-20) 
Otitis media (yes)   54 (35.8) 30 (17.1) 20 (18.2) 
Gastroenteritis (yes)    138 (92.0) 118 (69.0) 78 (72.2) 
Gastroenteritis (mean (min-max))  3 (0-11) 1 (0-5) 2 (0-5) 
Pneumonia (yes)    11 (7.3) 4 (2.3) 4 (3.6) 
Urinary tract infection (yes)  10 (6.7) 6 (3.5) 6 (5.5) 
Other chronic diseases (yes)  8 (5.1) 9 (5.1) 3 (2.7) 
Children’s diseases (yes)   76 (50.3) 36 (20.6) 25 (22.7) 
 Chicken pox    43 (28.5) 26 (14.9) 19 (17.3) 
 Exanthema subitum   45 (29.8) 8 (4.6) 5 (4.5) 
    
Gender (boy)    68 (43.0) 75 (42.6) 41 (36.6) 
Type of delivery (caesarean section) 18 (11.4) 21 (11.9) 14 (12.5) 
Birth season       
 March-August   27 (17.1) 34 (19.3) 21 (18.8) 
 September-February   131 (82.9) 142 (80.7) 91 (81.3) 
Apgar score 1 min (<7)   7 (4.4) 8 (4.5) 6 (5.4) 
Gestational age (mean (min-max)) 40 (37-42) wks 40 (37-42) wks 40 (37-42) wks 
Birth weight (mean (min-max)) 3554 (2292-4870) g 3555 (2292-4870) g 3525 (2292-4870) g 
Breast-feeding (no or <6 months)  19 (13.1) 21 (13.0) 15 (13.9) 
Start day-care centre (<12 months) 30 (19.4) 33 (19.1) 25 (22.5) 
Number older siblings (1) 72 (52.9) 83 (54.2) 49 (51.0) 
Parity (1)    82 (51.9) 93 (52.8) 56 (50.0) 
Previous breast-feeding     
 No     82 (51.9) 91 (51.7) 61 (54.5) 
 
12 months    39 (24.7) 45 (25.6) 27 (24.1) 
 >12 months    37 (23.4) 40 (22.7) 24 (21.4) 
Maternal asthma and allergy (yes)  66 (41.8) 68 (38.6) 45 (40.2) 
Paternal asthma and allergy (yes) 41 (26.8) 47 (27.5) 27 (24.8) 
Maternal age     
 <30     44 (27.8) 47 (26.7) 31 (27.7) 
 30-35    81 (51.3) 94 (53.4) 55 (49.1) 
 >35     33 (20.9) 35 (19.9) 26 (23.2) 
Maternal BMI     
 <20.0    27 (17.2) 30 (17.1) 17 (15.2) 
 20.0-24.9    95 (60.5) 101 (57.7) 69 (61.6) 
 >24.9    25 (22.3) 44 (25.1) 26 (23.2) 
Maternal education (years)      
 <13     31 (20.4) 38 (22.4) 14 (13.2) 
 13-16    65 (42.8) 68 (40.0) 49 (46.2) 
 >16     56 (36.8) 64 (37.6) 43 (40.6) 
Ever smoked (yes)   65 (41.1) 75 (42.6) 42 (37.5) 
Smoking during pregnancy (yes)  2 (1.3) 4 (2.3) 1 (0.9) 
Smoking last three months before pregnancy (yes) 24 (15.5) 27 (15.7) 12 (10.9) 
Passive smoking (yes)    10 (6.4) 11 (6.3) 9 (8.0) 
Gross income of the household (>700 000 NOK) 105 (68.2) 116 (67.4) 76 (69.7) 
Table 2. The calculated dietary intake of ndl-PCBs, dioxins and dl-PCBs, and acrylamide of the 
mothers in the BraMat cohort (n=200).  
Dietary toxicant     Mediana Min-max IQR 80th percentile
Ndl-PCBs (ng/kg bw/day) b   2.59 0.53-30.12 1.80-4.09 4.37 
Dioxins and dl-PCBs (pg TEQ/kg bw/day) c 0.58 0.15-3.07 0.45-0.81 0.90 
Acrylamide (g/kg bw/day)    0.56 0.07-2.05 0.41-0.72 0.79 
Note. IQR, interquartile range 
a The median values are presented since the data were not normally distributed. 
b PCB-28, 52, 101, 138, 153, and 180. 
c All 17 of the 2,3,7,8-substituted PCDD/PCDFs, non-ortho-substituted PCBs (PCB-77, 81, 126, and 
169), and mono-ortho-substituted PCBs (PCB-105, 114, 118, 123, 156, 157, 167, and 189). 
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Table 5. Results of bivariate and multivariatea analyses of prenatal dietary exposure to ndl-PCBs, 
dioxins and dl-PCBs, and acrylamide and sensitization (Phadiatop Infant) and vaccine titres. 
Serum analyses  Dietary toxicant  OR (95% CI) p-value aOR (95% CI) p-value 
        
Sensitization  Ndl-PCBs 1.72 (0.90–3.26) 0.099   
 Dioxins and dl-PCBs 1.52 (0.65-3.55) 0.329   
 Acrylamide 0.71 (0.29-1.74) 0.453   
      
   (95% CI) p-value a (95% CI) p-value 
Measles Ndl-PCBs -0.12 (-0.23- -0.01) 0.032 -0.12 (-0.23- -0.01) 0.032 
 Dioxins and dl-PCBs -0.15 (-0.29- -0.01) 0.036 -0.15 (-0.29- -0.01) 0.036 
 Acrylamide -0.13 (-0.29-0.02) 0.095 -0.13 (-0.29-0.02) 0.095 
Rubella Ndl-PCBs -0.05 (-0.16-0.06) 0.373   
 Dioxins and dl-PCBs -0.07 (-0.21-0.07) 0.335   
 Acrylamide -0.04 (-0.19-0.11) 0.620   
Tetanus b Ndl-PCBs 1.11 (0.92-1.32) 0.268   
 Dioxins and dl-PCBs 1.22 (0.97-1.54) 0.083 1.22 (0.97-1.54) 0.083 
 Acrylamide 1.25 (0.98-1.59) 0.076 1.25 (0.98-1.59) 0.076 
HiB b Ndl-PCBs 0.76 (0.56-1.02) 0.070 0.78 (0.58-1.04) 0.085 c 
 Dioxins and dl-PCBs 0.75 (0.51-1.11) 0.150   
 Acrylamide 1.22 (0.80-1.85) 0.349   
Pneumococcus b Ndl-PCBs 0.96 (0.81-1.15) 0.687   
 Dioxins and dl-PCBs 0.94 (0.75-1.18) 0.590   
 Acrylamide 0.94 (0.74-1.20) 0.627   
Note. Bold font, p<0.05; aOR, adjusted OR; a, adjusted . 
a Variables initially included in the multivariate analyses were: parity, maternal and paternal asthma 
and allergy, maternal age, maternal smoking, maternal passive smoking, maternal education, 
maternal BMI, mean parental gross income for the three years of the study, child’s gender, birth 
season, type of delivery, apgar score, gestational age, birth weight, breast-feeding of the child, and 
day-care attendance. 
b The outcome variable was ln-transformed, back-transformed values are reported (ratios).  
c Adjusted for gestational age and day-care attendance. 
 
 
 
 
 
Appendix A: 1-year follow-up questionnaire (Norwegian) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
BraMat 
Et delprosjekt i Den norske mor og barn-undersøkelsen 
 
 
Oppfølging av barnet ved fylte 1 år 
 
 
Vi gratulerer dere med 1 årsdagen! 
 
Vi har fra april 2007 til mars 2008 rekruttert 200 mødre og deres barn. Blodprøvene vi fikk 
av deg og barnet i forbindelse med fødselen blir nå analysert. Inntaket av fremmedstoffer 
(som steke-mutagener og andre miljøgifter) under svangerskapet beregnes ut fra 
spørreskjemaene som du har sendt inn til oss. 
 
Vi ønsker å følge barnet ditt til det er 3 år gammelt. I denne perioden vil vi følge utviklingen 
av barnets immunforsvar mot sykdom, spesielt allergi og infeksjoner, for å undersøke om 
fremmedstoffene kan ha påvirket barnets immunsystem. 
 
I denne studien opprettes også tilsvarende mor-barn prosjekter i Spania, Storbritannia, 
Hellas og Danmark. Data fra alle prosjektene vil bli sammenstilt. På den måten kan vi 
oppdage forskjeller og likheter mellom de ulike landene. 
 
Om kort tid vil vi kontakte deg per telefon for å spørre om hvilke sykdommer eller 
helseplager barnet ditt har hatt i løpet av sitt første leveår. På de neste sidene kan du 
lese de spørsmålene vi kommer til å stille deg i intervjuet. Bruk notatboken og 
helsestasjonskortet når du krysser av for spørsmålene.  
 
Dersom du ikke ønsker et telefonintervju, ber vi om at du fyller ut skjemaet og sender 
det til oss i vedlagte returkonvolutt innen en uke.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ID-nummer 
 Har barnet hatt noen av de følgende sykdommer/helseplager i 
alderen 0-12 mnd? Ja Nei 
Antall 
ganger 
Forkjølelse eller annen luftveissykdom 
 f.eks. falsk krupp, halsbetennelse, influensa, kikhoste    
Ørebetennelse    
Lungebetennelse    
Omgangssyke med oppkast eller diaré    
Urinveisinfeksjon    
 
Astma, allergi og andre kroniske sykdommer i alderen 0-12 mnd Ja Nei 
Har barnet fått diagnosen astma eller astmabronkitt av lege?   
Hvis ja, hvor mange måneder var barnet når det fikk diagnosen?  
Har barnet hatt perioder, som har vart i mer enn 10 dager, med tørrhoste, tetthet eller 
piping i brystet, eller kortpustethet?   
Har barnet eksem og kløe i ansiktet eller i bøyefurene på armer og ben? (f.eks. lyske, 
knehase, ankel, albubøy, håndledd)   
Har barnet fått diagnosen allergi av lege?   
Hvis ja, hvor mange måneder var barnet når det fikk diagnosen?  
Har barnet noen annen kronisk sykdom? 
 f.eks. diabetes (sukkersyke) eller leddgikt   
 
Har barnet hatt noen barnesykdommer i alderen 0-12 mnd? Ja 
 
Nei
 
Hvis ja, hvilke? 
 
Medisinbruk Ja Nei 
Bruker eller har barnet brukt astmamedisiner?   
Bruker eller har barnet brukt allergimedisiner?   
Har barnet fått antibiotika (penicillin eller lignende) mot infeksjoner? 
 f.eks. Apocillin, Calcipen, Weifapenin, Aboticin, Ery-Max, Imacillin   
Hvis ja, ved hvor mange infeksjoner har barnet fått behandling med antibiotika?  
 
 Vaksinasjon  
Kryss av for hvilke vaksiner barnet har fått i alderen 0-12 mnd  
 Ikke fått noen vaksine  
 DTP (Difteri, stivkrampe, kikhoste)  
 DT (Difteri, stivkrampe)  
 Polio – Hib (Hemophilus influenzae)  
 PKV (Pneumokokk)  
 MMR (Meslinger, kusma og røde hunder)  
 Hepatitt B (Engerix-B)  
 Annen vaksine  
 Hvis annen vaksine, beskriv: 
 
 
 
Fikk barnet bivirkninger av vaksineringen? Ja 
 
Nei 
 
Hvis ja, beskriv: 
 
 
 
 
 
 
 
 
Kommentarer 
 
 
Hva er barnets alder ved utfylling av dette skjemaet? 
Antall måneder  
 
Hvis dere lurer på noe i forbindelse med 1 års oppfølgingen, kan dere ringe til  
prosjektkoordinator Berit Granum, tlf. 21 07 66 96, 
stipendiat Solvor Berntsen Stølevik, tlf 21 07 62 57, 
eller sende e-post til bramat@fhi.no. 
 
Tusen takk for samarbeidet så langt! 

Appendix B: 1-year follow-up questionnaire (English) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Has the child had any of the following diseases/complaints at 0-12 
months of age? Yes No 
No. of 
times 
Cold or other respiratory diseases 
e.g. false croup, throat infection, influenza ,whooping cough      
Otitis media    
Pneumonia    
Gastroenteritis with vomiting or diarrhoea    
Urinary tract infection    
 
Asthma, allergy and other chronic diseases at 0-12 months of age Yes No 
Has the child been diagnosed with asthma or asthma bronchitis by a doctor?   
If yes, how old was the child when diagnosed?  
Has the child had periods of more than 10 days with dry cough, chest tightness or 
wheeze, or shortness of breath?   
Has the child had eczema or itching in the face or at joints? (e.g. groin, hollow of the 
knee, ankle, elbow, wrist)   
Has the child been diagnosed with allergy by a doctor?   
If yes, how old was the child when diagnosed?  
Does the child have any other chronic diseases? 
 e.g. diabetes or arthritis   
 
Has the child had any childhood diseases at 0-12 months of age? Yes 
 
No
 
If yes, which ones? 
 
Medication Yes No 
Does the child use or has used asthma medicine?   
Does the child use or has used allergy medicine?   
In case of infection, has the child used antibiotics (penicillin or similar)? 
e.g. Apocillin, Calcipen, Weifapenin, Aboticin, Ery-Max, Imacillin   
If yes, how many infections have been treated?  
 
 Vaccinations  
Tick off for the vaccines the child has been given at 0-12 months of age  
 No vaccines  
 DTP (Diphtheria, tetanus, whooping cough)  
 DT (Diphtheria, tetanus)  
 Polio – Hib (Hemophilus influenzae)  
 Pneumococcal vaccine  
 MMR (Measles, mumps, rubella)  
 Hepatitis B (Engerix-B)  
 Other vaccines  
 If other vaccines, describe: 
 
 
 
Did the child experience any side-effects upon vaccination? Yes 
 
No 
 
If yes, describe: 
 
 
 
 
 
 
 
 
Comments 
 
 
Fill in the child’s age 
No. of months  
 
 
 
Appendix C: 3-year follow-up questionnaire (Norwegian) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
BraMat 
Et delprosjekt i Den norske mor og barn-undersøkelsen 
 
 
Oppfølging av barnet etter fylte to år 
 
 
 
 
 
Om kort tid vil vi kontakte deg på telefon for å spørre om hvilke sykdommer eller 
helseplager barnet ditt har hatt etter fylte to år. Dersom du ikke ønsker et 
telefonintervju, ber vi om at du fyller ut skjemaet og sender det til oss i vedlagt 
returkonvolutt innen en uke. Bruk notatboken og helsestasjonskortet når du krysser 
av for spørsmålene.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ID-nummer 
   
 Opplysninger om barnet: 
Har barnet hatt noen av de følgende sykdommer/helseplager etter 
at det fylte to år? Ja Nei 
Antall 
ganger 
Forkjølelse eller annen luftveissykdom 
f.eks. falsk krupp, halsbetennelse, influensa, kikhoste, bihulebetennelse    
Ørebetennelse    
Lungebetennelse    
Omgangssyke med oppkast eller diaré    
Urinveisinfeksjon    
Feber uten andre symptomer enn slapphet    
 
 
Astma, allergi og andre kroniske sykdommer etter fylte to år Ja Nei 
Har barnet fått diagnosen astma, astmabronkitt eller bronkial hyperreaktivitet av 
lege?   
Hvis ja, hvor mange episoder har barnet hatt det siste året?  
Hvis ja, hvor gammelt var barnet da det fikk diagnosen?  
Har barnet hatt perioder, som har vart i mer enn 10 dager, med tørrhoste, tetthet eller 
piping i brystet, eller kortpustethet?   
Hvis ja, hvor mange episoder har barnet hatt det siste året?  
Har barnet hatt eksem og kløe i ansiktet eller i bøyefurene på armer og ben? (f.eks. 
lyske, knehase, ankel, albubøy, håndledd)   
Har barnet fått diagnosen atopisk eksem av lege?   
Hvis ja, hvor gammelt var barnet da det fikk diagnosen?  
Har barnet fått diagnosen allergi av lege?   
Hvis ja, hvor gammelt var barnet da det fikk diagnosen?  
Hvis ja, hva er barnet allergisk mot? 
 
 
 
Har barnet noen annen kronisk sykdom? 
f.eks. diabetes (sukkersyke) eller leddgikt   
Hvis ja, hvilke? 
 
 
 
 
 
Har barnet hatt noen barnesykdommer etter fylte to år? Ja 
 
Nei
 
Hvis ja, hvilke? 
 
 
 
 
 
  
Medisinbruk etter fylte to år Ja Nei 
Bruker eller har barnet brukt astmamedisiner?   
Bruker eller har barnet brukt allergimedisiner (ikke salver)?   
Har barnet fått antibiotika (penicillin eller lignende) mot infeksjoner? 
f.eks. Apocillin, Calcipen, Weifapenin, Aboticin, Ery-Max, Imacillin   
Hvis ja, ved hvor mange infeksjoner har barnet fått behandling med antibiotika?  
Hvis ja, ved hvilke infeksjoner har barnet fått behandling med antibiotika? 
Forkjølelse/annen luftveissykdom   Ørebetennelse    Lungebetennelse/bronkitt   Urinveisinfeksjon 
                                                                                                              
 
Hvis andre, hvilke? 
Har barnet fått andre medisiner?  
f.eks. febernedsettende og smertelindrende 
Ja 
 
Nei 
 
Hvis ja, oppgi navn på medisin 
 
 
Vaksiner etter fylte to år  
Har barnet fått noen vaksiner? Ja 
 
Nei 
 
Hvis ja, hvilke? 
 
Fikk barnet bivirkninger av vaksineringen? Ja 
 
Nei 
 
Hvis ja, beskriv: 
 
 
 
 
Informasjon om barnets hverdag fra fødsel fram til i dag 
I hvor mange måneder ammet du barnet?  
Hvor har barnet vært passet på dagtid (fra fødsel)? 
  
Barnets alder (mnd)       Hjemme          Dagmamma           Familiebarnehage       Barnehage                  
         Fra - til                            
                                                                                                                             
                                                                                                                             
                                                                                                                             
                                                                                                                                                  
Hvor mange eldre søsken/barn bor sammen med barnet?  
Oppholder barnet seg i rom hvor noen røyker? 
                                Nei                              Ja, av og til                        Ja, daglig            
                                                                                                                                              
 
 
 
 Opplysninger om barnets mor: 
Har du noen av disse sykdommene/helseplagene? Ja Nei 
Har du fått diagnosen astma av lege?   
Har du fått diagnosen allergi av lege?   
Hvis ja, hvilken type allergi har du? 
                    Luftveisallergi                              Matallergi                              Annen                                    
                (f.eks. pollen, dyr, midd)                                                      (f.eks. medisiner, kosmetikk, insekter)       
                                                                                                                  
Hvis annen, hva? 
Har du noen annen kronisk sykdom? 
f.eks. diabetes (sukkersyke) eller leddgikt   
Hvis ja, hvilke? 
 
 
 
 
Opplysninger om barnets far: 
Har barnets far noen av disse sykdommene/helseplagene? Ja Nei 
Har barnets far fått diagnosen astma av lege?   
Har barnets far fått diagnosen allergi av lege?   
Hvis ja, hvilken type allergi har barnets far? 
                    Luftveisallergi                              Matallergi                              Annen                                    
                (f.eks. pollen, dyr, midd)                                                      (f.eks. medisiner, kosmetikk, insekter)       
                                                                                                                  
Hvis annen, hva? 
Har barnets far noen annen kronisk sykdom? 
f.eks. diabetes (sukkersyke) eller leddgikt   
Hvis ja, hvilke? 
 
 
 
 
Husholdningens brutto inntekt 
Hva er husholdningens totale brutto inntekt per år (gjennomsnitt for de siste tre årene)? 
< 300 000 300 000-700 000 700 001-1 100 000 >1 100 000 
                   
 
Kommentarer 
 
 
Hva er barnets alder ved utfylling av dette skjemaet? 
Antall måneder  
Hvis dere lurer på noe i forbindelse med oppfølgingen, kan dere ringe til prosjektkoordinator Berit Granum, 
tlf. 21 07 66 96, stipendiat Solvor Berntsen Stølevik, tlf 21 07 62 57, eller sende e-post til bramat@fhi.no. 
Appendix D: 3-year follow-up questionnaire (English) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Information about the child: 
Has the child had any of the following diseases/complaints after 
turning 2 years of age? Yes No 
No. of 
times 
Cold or other respiratory diseases 
e.g. false croup, throat infection, influenza ,whooping cough, sinusitis      
Otitis media    
Pneumonia    
Gastroenteritis with vomiting or diarrhoea    
Urinary tract infection    
Fever without other symptoms than feeling weak    
 
 
Asthma, allergy and other chronic diseases after turning 2 years of age Yes No 
Has the child been diagnosed with asthma, asthma bronchitis, or bronchial 
hyperreactivity by a doctor?   
If yes, how many episodes during the last year?  
If yes, how old was the child when diagnosed?  
Has the child had periods of more than 10 days with dry cough, chest tightness or 
wheezing, or shortness of breath?   
If yes, how many episodes during the last year?  
Has the child had eczema or itching in the face or at joints? (e.g. groin, hollow of the 
knee, ankle, elbow, wrist)   
Has the child been diagnosed with atopic eczema by a doctor?   
If yes, how old was the child when diagnosed?  
Has the child been diagnosed with allergy by a doctor?   
If yes, how old was the child when diagnosed?  
If yes, what is the child allergic to? 
 
 
 
Does the child have any other chronic diseases? 
e.g. diabetes or arthritis   
If yes, which ones? 
 
 
 
 
 
Has the child had any childhood diseases after turning 2 years of age Yes 
 
No
 
If yes, which ones? 
 
 
 Use of medication after turning 2 years of age Yes No 
Does the child use or has used asthma medication?   
Does the child use or has used allergy medication (not salves)?   
In case of infection, has the child used antibiotics (penicillin or similar)? 
e.g. Apocillin, Calcipen, Weifapenin, Aboticin, Ery-Max, Imacillin   
If yes, how many infections have been treated?  
If yes, what kind of infections has been treated with antibiotics? 
      Cold/other airway diseases           Otitis media       Pneumonia/bronchitis      Urinary tract infection 
                                                                                                              
 
Others?  
Has the child been given other medicines?  
e.g. reducing fever or soothing pain 
Yes 
 
No 
 
If yes, give the name on the medicine 
 
 
Vaccines after turning 2 years of age 
Has the child been given any vaccines? Yes 
 
No 
 
If yes, what kind of vaccines? 
 
Did the child experience any side-effects upon vaccination? Yes 
 
No 
 
If yes, describe: 
 
 
 
 
Information about the child’s everyday life from birth till today 
How many months did you breast-feed your child?  
Where has the child stayed in the daytime (from birth)? 
  
Child’s age (months)       At home          Childminder               Kindergarten         Kindergarten                
         From-till                                                                           (small group) 
                                                                                                                             
                                                                                                                             
                                                                                                                             
                                                                                                                                                  
How many older siblings/children live together with the child?  
Does the child stay in rooms together with somebody smoking? 
                                No                         Yes, sometimes                        Yes, daily            
                                                                                                                                              
 
 
 
Information about the mother: 
Do you have any of these diseases/complaints Yes No 
Have you been diagnosed with asthma by a doctor?   
Have you been diagnosed with allergy by a doctor?   
If yes, what kind of allergy do you have? 
                Respiratory allergy                        Food allergy                           Other 
             (e.g. pollen, animals, mite)                                                      (e.g. medicines, cosmetics, insects)       
                                                                                                                  
If others, describe: 
Do you have any other chronic diseases? 
e.g. diabetes or arthritis   
If yes, describe: 
 
 
 
 
Information about the father: 
Has the father any of these diseases/complaints Yes No 
Has the father been diagnosed with asthma by a doctor?   
Has the father been diagnosed with allergy by a doctor?   
If yes, what kind of allergy do you have? 
                Respiratory allergy                        Food allergy                           Other 
             (e.g. pollen, animals, mite)                                                      (e.g. medicines, cosmetics, insects)       
                                                                                                                  
If others, describe: 
Has the father any other chronic diseases? 
e.g. diabetes or arthritis   
If yes, describe: 
 
 
 
 
Gross income of the household 
What is the total gross income of the household per year (mean of three last years)? 
< 300 000 300 000-700 000 700 001-1 100 000 >1 100 000 
                   
 
Comments 
 
 
Fill in the child’s age 
No. of months  
 

